

CURRICULUM VITAE

CONTACT INFORMATION:

Name: **Carmen Criscitiello**

Date and Place of Birth: November 22, 1980; Avellino, Italy

Work Address: European Institute of Oncology
Via Ripamonti, 435 - 20141
Milano, Italy

E-mail address: carmen.criscitiello@ieo.it
carmen.criscitiello@unimi.it

EDUCATION

16 October 2005: M.D. Degree, Medical School, University of Naples “Federico II”, Italy

18 January 2010: Residency in Oncology, University of Naples “Federico II”, Italy

16 January 2013: PhD in Medical Oncology and Surgery and Clinical Immunology, Division of Medical Oncology, Seconda Università degli Studi di Napoli (SUN), Italy

PROFESSIONAL EXPERIENCE

April 2025 – present: Director Precision Oncology Unit, European Institute of Oncology – Milano, Italy

May 2024- present: Associate Professor, University of Milan, Italy

November 2020 – April 2024: Assistant Professor, University of Milan, Italy

January 2018- present: Scientist & Senior Staff Member appointed with High Specialty in Immunotherapy at the Division of Experimental Therapeutics, European Institute of Oncology – Milano, Italy

July 2016: Visiting Physician at the Breast Cancer Department, Dana Farber Cancer Institute, Boston U.S.A.

January 2015-present: Scientist & Senior Staff Member, Division of Experimental Therapeutics, European Institute of Oncology – Milano, Italy

June 2014: Visiting Researcher at the M.D. Anderson Cancer Center, Houston U.S.A.

October 2011-December 2014: Fellowship in Medical Oncology, Division of Medical Oncology, European Institute of Oncology – Milano, Italy

April 2009- September 2011: TransBIG Fellowship, Translational Research Unit, Institut Jules Bordet - Brussels, Belgium

2003-2005: Internship, Division of Medical Oncology, Medical School, University of Naples “Federico II”, Italy

TEACHING EXPERIENCE

A.Y. 2023/2024

- Teaching of *Medical Oncology* – School of Specialization in Oncology, University of Milan
- Teaching of *Clinical Omics* – Master's Degree in *Biomedical Omics*, University of Milan
- Teaching activity in the *PhD program in Translational Medicine*, University of Milan
- Coordinator and lecturer – *Postgraduate Course in Artificial Intelligence in Medicine*, University of Milan
- Lecturer – *Postgraduate Course in Methodology and Ethics of Clinical Oncology Trials*, University of Milan
- Lecturer – *Postgraduate Course in Breast Cancer Prevention*, University of Milan

A.Y. 2022/2023

- Teaching of *Medical Oncology* – School of Specialization in Oncology, University of Milan
- Teaching of *Clinical Omics* – Master's Degree in *Biomedical Omics*, University of Milan
- Teaching in the *Master in Artificial Intelligence & Machine Learning in Cancer Medicine*, University of Milan
- Teaching in the *PhD program in Translational Medicine*, University of Milan
- Lecturer – *Postgraduate Course in Methodology and Ethics of Clinical Oncology Trials*, University of Milan
- Co-supervisor of theses – Degree Course in Medicine and Surgery IMS, University of Milan
- Co-supervisor of theses – School of Specialization in Oncology, University of Milan

A.Y. 2021/2022

- Teaching of *Medical Oncology* – School of Specialization in Oncology, University of Milan
- Teaching of *Clinical Omics* – Master's Degree in *Biomedical Omics*, University of Milan
- Teaching activity in the *PhD program in Translational Medicine*, University of Milan
- Co-supervisor of theses – Degree Course in Medicine and Surgery IMS, University of Milan
- Co-supervisor of theses – School of Specialization in Oncology, University of Milan

A.Y. 2020/2021

- Teaching of *Medical Oncology* – School of Specialization in Oncology, University of Milan
- Co-supervisor of specialization thesis – University of Milan
- Seminar for specialization students at the University of Campania “Luigi Vanvitelli”:
“*Systemic therapy of triple-negative breast cancer*”

2013 – 2019

- 2013 – Lesson “*Cancer Clinical Trials in the Genomic Era*” – SEMM
- 2013 – Lesson “*New Drugs for Breast-Cancer Subtypes*” – SEMM
- 2014 – Seminar “*Tumour-Infiltrating Lymphocytes in Breast Cancer*” – MD Anderson Cancer Center, Houston
- 2016 – Post-ASCO teaching activity for specialization students – University of Milan
- 2019 – Post-ESMO teaching activity for specialization students – University of Milan

MAIN RESEARCH ACTIVITIES

- **ALPHABET study**

Randomized phase III trial of trastuzumab + alpelisib ± endocrine therapy vs trastuzumab + chemotherapy in patients with HER2-positive, PIK3CA-mutated advanced breast cancer.

Role: Global Principal Investigator.

- **TIP study**

Real-world study on the efficacy and tolerability of atezolizumab + nab-paclitaxel as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.

Role: Principal Investigator.

- **SISTER study**

Retrospective observational study on PFS2 in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Role: Principal Investigator.

- **HER2DX-Breast-DX study**

Prospective observational study to evaluate the clinical impact of the HER2DX assay on treatment decisions in early-stage HER2-positive breast cancer.

Role: Principal Investigator.

- **HER2-loss study**

Study of HER2 expression loss on residual disease in HER2-positive early breast cancer patients treated with neoadjuvant therapy.

Role: Principal Investigator.

- **Decoding brain metastases project**

Spatial single-cell transcriptomic analysis of breast cancer brain metastases in collaboration with the Cancer Research UK Cambridge Institute and Istituto Besta.

Role: Co-Principal Investigator.

- **Genomic and immune profiles of HR-loss in metastatic breast cancer**

Study conducted in collaboration with Institut Gustave Roussy, focusing on the biological implications of hormone receptor loss.

Role: Co-Principal Investigator.

- **Intratumoral and temporal heterogeneity of immune biomarkers**

Analysis of heterogeneity in metastatic breast cancer tissue, in collaboration with CRUK Cambridge.

Role: Co-Principal Investigator.

- **Impact of autoimmune diseases on outcomes in early breast cancer**

Retrospective study evaluating disease-free and overall survival in patients with autoimmune comorbidities.

Role: Principal Investigator.

- **Psychosocial implications of remote vs on-site working in breast cancer patients**

Study on emotional, cognitive, and social well-being in patients with breast cancer during and after

the COVID-19 pandemic.

Role: Co-Principal Investigator.

- **ANASTASE real-world study**

Study on the use of atezolizumab + nab-paclitaxel in first-line PD-L1-positive metastatic TNBC.

Role: Principal Investigator.

COMPETITIVE RESEARCH GRANTS

- **01/01/2022 – 30/03/2022**

Scientific Coordinator of the project “**Let’s Talk About Cancer**”

Funder: Seagen (€25,000)

Educational initiative aimed at patients with breast cancer to improve doctor–patient communication through webinars, informational events, and interactive digital tools.

- **01/01/2022 – 31/12/2023**

Scientific Coordinator of the project “**Characterization of genomic and immune profiles associated with loss of hormone receptor expression in metastatic breast cancer**”, in collaboration with Gustave Roussy (Paris)

Funder: Gilead Sciences S.r.l. (€25,000)

Study aimed at identifying mechanisms of endocrine resistance through multi-omic profiling and integrated clinical data analysis.

- **From 01/01/2023 – ongoing**

Principal Investigator of the project “**PSR 2022 – Enhancing HER2 spatial heterogeneity assessment in HER2-Low breast cancer: A deep learning approach on a computational pathology platform**”

Funder: University of Milan (€37,000)

Project exploring the application of artificial intelligence to assess spatial HER2 heterogeneity in HER2-low breast cancer.

- **From 01/01/2024 – ongoing**

Principal Investigator of the project “**Prospective observational monocentric study to evaluate the impact of the HER2DX assay on treatment decisions in early-stage HER2+ breast cancer**”

Funder: Fondazione Umberto Veronesi (€150,000)

Prospective study evaluating the clinical impact of HER2DX on personalized treatment decision-making in early-stage HER2-positive breast cancer.

- **From 01/01/2024 – ongoing**

Scientific Coordinator of the project “**Characterization of genomic and immune profiles associated with loss of hormone receptor expression in metastatic breast cancer – longitudinal analysis**”, in collaboration with Gustave Roussy (Paris)

Funder: Gilead Sciences S.r.l. (€32,000)

Project extension focused on longitudinal evolution of genomic and immune profiles and identification of novel therapeutic targets in hormone-resistant breast cancer.

SCIENTIFIC PRODUCTIVITY AND BIBLIOMETRIC INDICATORS

- Author of 220 peer-reviewed publications

- H-index: 51
- Citations: 12,770 (Scopus)
- Co-investigator in over 200 clinical trials
- Patent 16305838.1 (2017): Predictive gene signature of lymphocytic infiltration in triple-negative breast cancer (TNBC) – TRANSCAN project in collaboration with Gustave Roussy (Paris)

HONORS AND AWARDS

May 25, 2024: 2024 Awarded the 2024 Leonardo Di Capua National Scientific Award

February 5, 2024: A grant of 150,000 euros awarded by the Umberto Veronesi Foundation in support of the project 'Impact of the HER2DX assay on treatment decisions in patients with early-stage HER2+ breast cancer'

February 5, 2024: Awarded the 'Italian Excellence 2024' Award, in the Capitol Hall of the Senate of the Republic

2024: Scientific Committee Member for ESMO Breast Cancer 2024 annual meeting – Berlin, Germany

2023-2024 Mentor for the third edition of the ESMO Virtual Mentorship Programme

2023: Scientific Committee Member for ESMO Breast Cancer 2023 annual meeting – Berlin, Germany

2023-2024: Scientific Committee Member for EBCC 14 – Milan, Italy

2023: Faculty member for ESO Masterclass in Clinical Oncology: Autumn edition - Varese, Italy

2022-2023 Mentor for the AIOM Mentorship Programme

2022-2023: Scientific Committee Member for EBCC 13 - Barcelona, Spain

2022: Grant (25.000 euros) from Gilead Sciences s.r.l. for the project “Characterization of genomic and immune profiles associated with loss of hormone receptor expression in metastatic breast cancer”

2020 – 23/01/2023 ESMO Leadership Generation Task Force Deputy Chair

2018 - to date: AIOM Breast Cancer Guidelines Panel Member

2018- 23/01/2023: Member of the ESMO Press & Media Affairs Committee

24/01/2023-31/12/2024 Member of the ESMO Communication Committee

January 2018: "Back from San Antonio" Award for the best publication

2017-to date: National Scientific Qualification as Associate Professor of Oncology

2017-to date: ESMO faculty member for the Breast cancer faculty group

2016: ESMO Leaders Generation Programme

2014: Member of the Scientific Committee for Metastatic Breast Cancer at the 2014 ESMO annual meeting – Madrid, Spain

EDITORIAL BOARDS

January 2024 – to date: Editor for Breast Cancer Section of the European Journal of Cancer

January 2021 – to date: Associate Editor for Frontiers in Oncology - Board of Breast Cancer

October 2019 – to date: Associate Editor for Frontiers in Oncology - Board of Women's Cancer

2019 – to date: ESMO Open Editorial board member, Breast Cancer

2019: Associate Editor for the ESMO 2019 Congress Newspaper

2018: Associate Editor for the ESMO 2018 Congress Newspaper

January 2018- to date: ESMO Open - Cancer Horizons

REVIEWER ACTIVITY

Lancet Oncology, Annals of Oncology, European Journal of Cancer, Journal of Translational Medicine, The Breast, The Oncologist, NPJ

MEMBERSHIPS AND AFFILIATIONS

2008- to date: Member of the European Society of Medical Oncology (ESMO)

2013-to date: Member of the Associazione Italiana di Oncologia Medica (AIOM)

2016-to date: Member of the Breast Cancer Working Group for *Alleanza Contro il Cancro* (ACC)

PERSONAL SKILLS AND COMPETENCES:

Mother Tongue: Italian

Other Languages: English and French

LIST OF PRESENTATIONS AT SCIENTIFIC MEETINGS:

- June 27-28, 2025 Pescocostanzo Italy Breast Cancer: Progresses and Perspectives. Invited talk: “Systemic treatments for HER2-low tumors: state of the art and therapeutic algorithm”
- June 26-27, 2025 Milano Italy The optimal management of patients with HR+ HER2- breast cancer. Invited talk: “Early stage HR+ HER2- breast cancer”
- June 19, 2025 Milano Italy Scientific Director at the ECM/FSC Improvement Group event "Harmonization of diagnostic procedures for accurate treatment selection: a focus on breast carcinoma". Invited speaker: “The therapeutic news”
- June 16-17, 2025 Milano Italy Landscapes 2025 In Oncology- Innovative therapies in Oncology. Invited talk: “Adjuvant and Neoadjuvant therapy in HR+/HER2- early breast cancer”
- June 6-7, 2025 Milano Italy Preceptorship in gynecological e breast cancer. Invited talk: “HER2+ breast cancer: Systemic therapy for metastatic breast cancer”
- June 6-7, 2025 Genova Italy YBO (young breast oncologists) 5th edition unmet needs in breast cancer care. Invited talk: “News in patient selection, chemotherapy and endocrine therapy approaches”
- May 23-24, 2025 Iseo Italy LIFE 2 WOMEN – The treatment of HR+ HER2-: from the adjuvant to the metastatic setting
- May 19-20, 2025 Milano Italy “hyperAKTion 2.0 – The patient journey in HR+/HER2– breast cancer with mutations in the AKT pathway”. Invited talk: “PIK3CA/AKT1/PTEN mutations in breast cancer: what is their clinical significance?”
- May 14-17, 2025 Munich Germany, ESMO Breast Cancer 2025 “Expert Perspectives: Sequencing Treatments in Patients with HER2+ Metastatic Breast Cancer”, invited talk:” Where are we today: understanding the evolving treatment landscape of HER2+ metastatic breast cancer”
- May 12, 2025 Milano Italy Scientific Lead of the national multidisciplinary project “National Multidisciplinary Project for the Analysis of Clinical Scenarios in the Treatment of Patients with HER2-low Metastatic Breast Cancer”
- May 9-10, 2025 Milano Italy "NEXT Oncology. Supporting Oncology through Innovation". Invited speaker at the Round table discussion on “Omics Profiling in Precision Oncology”
- May 5-6, 2025 Milano Italy “Annual Breast Cancer Conference: Maximising benefits by newer agents”. Invited talk: “Advances in Digital Pathology: Artificial Intelligence Applications for Tumor Characterization”
- April 16-17, 2025 Inveruno (MI) Italy Oncology Atelier. Invited talk: “Post-neoadjuvant treatment: adjuvant therapy selection”

- April 7-8, 2025 Padova Italy “B.I.T. Breast In Translation 2.0”. Invited talk: “State-of-the-art of ADC use in breast cancer treatment”
- April 4, 2025 Prato Italy “PRATO (Perspectives and Research Advancements in Oncology) – Breast Cancer”. Invited talk: “Treatment targets for metastatic breast cancer: HER2”
- April 3, 2025 Milan Italy “Best in Breast”. Invited talk: “Validation of evidence and MCBS of CDK4/6 inhibitors in the metastatic setting: the ESMO perspective”
- April 1, 2025 Milan Italy “The revolution of next-generation ADCs in the treatment of breast cancer”. Invited talk: “How to detect and treat T-DXd-related pneumonitis early: the importance of radiologic timing and clinical assessment”
- March 27-28, 2025 Milan Italy Evolver
- March 26-28, 2025 Madrid, Spain - GEICAM International Meeting. TABLE 3: Positioning combined medication: where, how, when and why. Invited talk: State of the Art
- March 21-22, 2025 Teramo Italy - Valuing time: new therapeutic pathways, integrated treatments, and new organizational models in early-stage breast cancer. Invited talk: lights and sheds in the adjuvant treatment of HR+/HER2- breast cancer.
- March 7-8, 2025 Napoli, Italy Breast Journal Club. Invited speaker: updates in early stage TNBC
- February 20-21, 2025 FOCUS SUL CARCINOMA MAMMARIO. Udine –Italy. Invited talk: “Top-five from SABCS”
- February 14, 2025 “Hereditary breast cancer: an evolving model”. Bologna, Italy. Invited talk: “Therapeutic algorithm and news in early stage triple-negative breast cancer”.
- January 30, 2025 SEM “TIME2GETHER” “The treatment of HR+ HER2- breast cancer: A path to design together”. Bologna, Italy. Scientific responsible and chairman
- January 13, 2025 “Real world data and shared decision making: Navigating the intersection of quality, cost and survival”. Webinar- scientific responsible and chairman
- January 10-11, 2025 Back from San Antonio, Genova Italy. Invited talk “biological news in HER2+ disease”
- December 13-14, 2024 Milano Italy “Preceptorship in predictive molecular pathology of breast cancer: Focus on the PIK3CA pathway in HR+/HER2- breast cancer between tissue and liquid biopsy”. Invited Talk: “The clinical complexity of HR+/HER2- breast cancer”
- December 9, 2024 webinar “Interbreast conference”. Invited speaker: “immunotherapy in breast cancer: has the time come?”
- December 6-7, 2024 Napoli Italy “Multidisciplinary management of breast cancer”. Invited talk: “updates in the treatment of early breast cancer”
- December 5, 2024 Como Italy “reshape the practice in HR+/HER2- breast cancer”. Scientific responsible.
- November 30, 2024 Bologna Italy Bologna “the pathway of cure for patients with breast cancer “. Invited talk: “How to integrate PARPi in the therapeutic strategy”
- November 29-30, 2024 Napoli Italy “Preceptorship in predictive molecular pathology of breast cancer: Focus on the PIK3CA pathway in HR+/HER2- breast cancer between tissue and liquid biopsy”
- November 28-29, 2024 Desenzano Italy. “Innovation and challenges in the treatment of breast cancer: how to deal with the open questions”. Scientific responsible.
- November 25, 2024 Roma Italy. “Ubi maior...minor docet”. Invited talk: “the patient with metastatic breast cancer”
- November 21-22, 2024 Milano Italy Breastalk, national forum on breast cancer. Invited talk: “the treatment of HER2-positive metastatic breast cancer”
- November 19-20, 2024 webinar “Neoadjuvant treatment in breast cancer. News from the research and practical application”. Invited talk: “useful data from real world”
- November 18-19, 2024 Napoli Italy. Translational Research in Breast Cancer WORKSHOP

- November 8-10, 2024 Rome Italy AIOM Medical Oncology Annual Meeting. Invited talk in the educational session on: “to treat or not to treat: de-escalation in HER2+ and triple-negative breast cancer”
- November 7-9, 2024 Giardini Naxos (ME) Italy SIAPEC-IAC Annual Meeting. Invited talk:” New scenarios in precision diagnostics for patients with HER2-low breast cancer”
- October 24-25, 2024 Padua Italy. “20th Meet the Professor. Advanced International Breast Cancer Course (AIBCC). Invited talk:”HR+ disease: Adapting the algorithm in a contemporary scenario”
- October 23-25, 2024 Barcelona Spain. “36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics”. Invited talk: “The rationale for combination of CDK4/6 inhibitors with other medicines”
- October 16, 2024 Milan Italy. "Let's Talk About Cancer – from patients' questions to oncologists' answers" – Scientific responsible.
- October 15, 2024 Milan Italy. “Optimizing outcomes in early-stage TNBC: a multidisciplinary approach to immunotherapy management”. Scientific responsible, and invited speaker: ”post-neoadjuvant treatment after pCR and RD”
- October 10, 2024 Pavia Italy. “Post-ESMO Meeting”. Invited talk:”Update in breast cancer”
- October 9, 2024 Bergamo Italy. “WE BRCA Breast 2.0”. Invited talk:”The toxicity of PARP inhibitors”
- September 26, 2024 Milano, Italy. The evolution in the treatment of HR+/HER2- breast cancer. Scientific responsible.
- September 26, 2024 Milano, Italy. Predictive pathology in breast cancer.
- September 20-21, 2024 Udine, Italy. GIM Annual Meeting. Invited talk: ”The innovation in breast cancer research: early stage triple-negative breast cancer”
- September 13-17, 2024 ESMO 2024, Barcelona, Spain. Mini Oral Session, chair and Invited Discussant 347MO, 348MO and 349MO
- September 13-17, 2024 ESMO 2024, Barcelona, Spain. Maximising the Metastatic Breast Cancer Treatment Paradigm and Looking Ahead
- September 12, 2024 webinar “PIK3CA in metastatic HR+/HER2- breast cancer”. Invited talk: ”Tissue or liquid biopsy?”
- September 11, 2024 "Recognizing oneself beyond cancer: Psychophysical and sexual well-being after a breast cancer diagnosis"
- September 10, 2024 Milano. Shared decision making in breast cancer, invited discussant
- September 9, 2024 Florence 36th European Congress of Pathology. Invited talk:” The ADC revolution in breast cancer: clinical aspects and possible impacts for pathologists”
- July 19, 2024 “HER2LOW: Challenges and Opportunities in Pathological Anatomy”. Invited talk:” News for the treatment of breast cancer”
- July 4, 2024 Milano, Pharmacological Interaction, Oncological Treatments, Adherence, and Psychological Discomfort. Invited talk:” Main Challenges in Pharmacological Interactions with Anticancer Drugs”
- July 1, 2024 Pisa Growing in Group. Invited talk:”Molecular test (BRCA, PIK3CA, ESR1)”
- June 24, 2024 IBU BC Hybrid VCOE - Clinical Case Discussions from International Faculty.
- June 20-21, 2024. Roma “EVOLVE - Evolving Landscape in HR+/HER2- mBC”. Invited talk: “primary endocrine resistance in patients with mBC
- June 13-14, 2024. Genova "YBO: Unmet needs in breast cancer care”. Invited talk: the evolving landscape of adjuvant endocrine-based therapy"
- June 2024, ESO Summer Masterclasses in Clinical Oncology, Novel approaches in Oncology. Invited talk: "Oligometastatic disease"

- May 28-30, 2024 Milan PhD Students Meeting. Lecture: "Approaches in Oncology Research"
- May 25, 2024 Bagnoli Irpino Cancer meeting. Invited talk: "Therapeutic advancements in the treatment of breast cancer"
- May 23-24, 2024 Milan "HER2 Spectrum: navigating the new frontiers in mBC", invited talk: "HER2-positive disease"
- May 22, 2024 Milan. "Metastatic HER2+ disease: how today's tools help us improve the future of our patients" scientific director and invited speaker: "Therapeutic highlights in the treatment of patients with Her2+ metastatic breast cancer: the evolution of therapeutic sequences"
- May 18-19, 2024 Milan International preceptorship on breast cancer - Multidisciplinary management, standards of care, therapeutic targets and future perspectives. Invited talk: "Systemic therapy for metastatic HER2+ breast cancer"
- May 15-17, 2024 ESMO Breast Cancer 2024, Berlin, Germany - Scientific Committee expert and invited speaker: "Moving forward: A case-based conversation on clinical decision-making in 3L post T-DXd progression and future directions in HER2+ MBC"
- May 15-17, 2024 ESMO Breast Cancer 2024, Berlin, Germany - Scientific Committee expert and invited speaker: "HR-positive/HER2-negative: When to use CDK4/6 inhibitors, including gBRCA1/2mut patients?"
- May 13, 2024 Como, "EXPERTS IN DISCUSSION: MANAGING PATIENTS WITH HR+/HER2- BREAST CANCER",. Invited talks: "'CDK4/6 Inhibitors: Update on Efficacy Data for HR+ HER2- MBC and Decision-Making Algorithm" and "CDK4/6 Inhibitors: Update on Efficacy Data for HR+ HER2- EBC"
- May 13, 2024 Webinar "Consensus Evolve – Evolving Landscape in HR+/HER2- MBC". Invited talk: "definition of endocrine resistance and endocrine sensibility"
- May 11-12, 2024 Milan International preceptorship on breast cancer - Multidisciplinary management, standards of care, therapeutic targets and future perspectives. Invited talk: "Systemic therapy for metastatic HER+ breast cancer"
- May 9-10, 2024 Milan "the practical management of patients with HR+/HER2- breast cancer, a shared path". Invited talk: "sharing experience in metastatic HR+ HER2- breast cancer"
- May 9, 2024 Milan "Breastaverse An immersive journey", Scientific Responsible
- May 6, 2024 Catania Italy, ONE DAY WITH THE EXPERT AT HICC "Drugs or knife? Surgical de-escalation depends on pharmacological treatment". Scientific Responsible and invited speaker: "Primary pharmacological treatment and surgical de-escalation. How to gain the opportunity?"
- May 3-4, 2024 Desenzano (BS) Italy, "The treatment of HR+ HER2 breast cancer: from adjuvant to metastatic" invited speaker: "Is it possible to omit radiotherapy after breast-conserving surgery? The oncologist's point of view"
- April 23, 2024 webinar "Sharing experience in advanced breast cancer" scientific responsible
- April 22, 2024 Napoli Italy "Shared decision medicine in breast cancer". Invited discussant.
- April 18-19, 2024 Prato Italy "PRATO (Perspectives and Research AdvancemenTs in Oncology) – Breast cancer". Invited talk: "Tackling endocrine resistance in the clinic: new endocrine agents and combinations"
- April 16, 2024 BrEaST in practice @IEO, Milan Italy. Invited talk: "early breast cancer"
- April 15, 2024 Mantova Italy TALKING TO THE EXPERT. Invited talk: "Lecture: State of the art in the management of HR+ HER2- breast cancer: from the adjuvant to the metastatic setting"

- April 12, 2024 Roma Italy Changing therapeutic paradigms in early and advanced breast cancer. Invited talk: Optimal management in HER2 positive metastatic breast cancer
- April 8, 2024 Inveruno (MI) Italy Oncology Atelier. Invited talk: Post-neoadjuvant treatment: adjuvant therapy selection
- April 4-5, 2024 Padova, Italy Breast Journal Club. Invited speaker: best paper presentation and place in therapy
- April 3, 2024 webinar “PIK3CA in HR+/HER2- metastatic breast cancer towards a more and more personalized diagnosis”. Invited speaker: the role of ruolo PIK3CA mutations in patients with HR+/HER2- MBC: analysis of clinical trials
- March 25, 2024 The management of patients undergoing immunotherapy treatment." Milan, Italy.
- 14TH EBCC Congress 2024 Milan, Italy 20-22 March 2024 This House Believes That Pembrolizumab Needs to be Continued as Post-Neoadjuvant Treatment in Patients with TNBC Disease Session type: Debate. Speaker against
- 14TH EBCC Congress 2024 Milan, Italy 20-22 March 2024 “Awareness, Development, Consideration: The A-D-C of Metastatic Breast Cancer Care”. Invited talk “Consideration: Maximising the Benefit of ADCs in mBC”
- March 14-15, 2024 Evolver 2024. Abemaciclib, una storia diVERsa Torino. Break-out session– interactive discussion on visceral metastases.
- March 8, 2024 Women 4 Women, webinar. “shared decision making”
- February 29, 2024 " Immunotherapy in the treatment of non-metastatic TNBC" Milan, Italy. Invited talk: "The Immunotherapy: Specific Management Needs"
- February 22-23, 2024 FOCUS SUL CARCINOMA MAMMARIO. Udine –Italy. Invited talk: ”Top-five from SABCS”
- February 16, 2024 "The management of patients undergoing immunotherapy treatment." Milan, Italy. Invited talk: "The practical management of breast cancer patients: the importance of the team."
- January 31, 2024 AIOM webinar, “Returning from SABCS”. Invited talk: “news on Luminal breast cancer”
- January 26, 2024 RØvolution: WEB & Social Media in Oncology, Milano Italy. Invited talk “the role of clinical trials in metastatic breast cancer”
- January 25, 2024 time2evolve - Scientific Exchange Meeting, Firenze Italy. Scientific responsible and moderator
- January 20-21, 2024 Preceptorship breast cancer, Milan Italy. Invited talk “Adjuvant endocrine therapy and biologics (Risk Assessment Stratification and criteria in early Breast Cancer)”
- January 12-13, 2024 Back from San Antonio, Genova Italy. Invited talk “biological news in HER2+ disease”
- January 11, 2024 “Real world data and shared decision making - How real-world data can help to solve the equation between quality, cost and survival”, webinar- scientific responsible and chairman
- December 17, 2023 Milan Breast Cancer Preceptorship. Invited talk: “Adjuvant endocrine therapy and CDK 4-6 inhibitors”
- December 16, 2023 Bologna “the pathway of cure for patients with breast cancer “. Invited talk:” 2023 updates and new perspectives in mTNBC”
- December 13-16, 2023 MBN2023 oncoplasic breast meeting – masters and promises, Milan Italy. Invited talk on ”What is new in primary systemic therapies for breast cancer”
- December 13-16, 2023 MBN2023 oncoplasic breast meeting – masters and promises, Milan Italy. Invited talk on ”Non-surgical risk reduction”

- December 13, 2023 “Breast Cancer Multidisciplinary Management” Virtual Meeting, invited talk on “updates of the year on HR+/HER2- metastatic breast cancer”
- November 29, 2023 Bologna “Reshape the practice”, scientific responsible
- November 28, 2023 Bridge the gap, breast edition, Milano. Invited talk:” development of a shared report”
- November 27, 2023 Milano “Young breast oncologists. The new treatments for HER2-positive metastatic breast cancer, with a special focus on trastuzumab deruxtecan” Scientific responsible and invited talk on “The new treatment algorithm for patients with HER2-positive metastatic breast cancer”
- November 23, 2023 Rome. Realness-Touch the new possible in mTNBC treatment”. Invited speaker “touch the balance”
- November 22, 2023 AIOM webinar I mercoledì dell’oncologia. Invited speaker “breast cancer news from ESMO 2023”
- November 21, 2023 Rome The oncology Olympics, chairman
- November 16-17, 2023 Reggio Emilia "8th International Congress CLINICAL NEEDS AND TRANSLATIONAL RESEARCH IN ONCOLOGY". Invited talk:” Neoadjuvant immunotherapy in triple negative breast cancer”
- November 11, 2023 Rome “SHAPING HER STORY: The new treatment algorithm for patients with HER2-positive metastatic breast cancer. Invited talk: ”Talking about HER journey”
- October 27-28, 2023 Novara Innovators in Breast Cancer after ESMO 2023 – Chairman “How early stage breast cancer’s clinical practice will change after ESMO 2023?”
- October 26 2023 ReLive ESMO 2023 Invited talk:” updates in TNBC?”
- October 17, 2023 Milan “Breast practice. Use of genomic signatures for breast cancer treatment decision-making in special clinical scenarios”. Invited talk:” What’s new in the use of genomic signatures for premenopausal women with early breast cancer?”
- October 16, 2023 Milan "Let's Talk About Cancer – from patients’ questions to oncologists’ answers" – Scientific responsible.
- October 9-10, 2023 Milan "NEXT Oncology. Supporting Oncology through Innovation". Round table Nanomedicine and precision medicine
- October 7-10, 2023 Varese "Masterclass in Clinical Oncology - Autumn edition”. Breast cancer tumour board and breast cancer clinical cases.
- October 3, 2023 Webinar HER2Low, advise on virtual slide. Invited talk:” “HER2low: the importance of the diagnosis”
- September 29, 2023 Bridge the gap, breast edition, Milano 2023. Invited talk:” landscape evolution in the treatments for patients with metastatic breast cancer”
- September 29, 2023 Breast Cancer in Autumn – Milano. Invited talk:” How clinical practice is evolving inHER2+ breast cancer based on literature news”
- September 28, 2023 Milan. Treatment evolution in HR+, HER2- breast cancer, scientific responsible and invited speaker: ”new data for the treatment of adjuvant HR+, HER2- breast cancer”
- September 27-29, 2023 Florence AIS attualità in senologia. Invited talk:”immunotherapy in breast cancer”
- September 18-19, 2023 Roma. New world: onconnauts in navigation #discoverHER. Invited talk: ”The compass to orient yourself along the journey. Dialogue with the expert: the 4 cardinal points”
- September 15-16, 2023 Roma GIM meeting. Invited talk:”updates metastatic triple-negative breast cancer”
- September 13-16, 2023 Verbania International Summer School on Immuno-Oncology 3rd edition. Invited speaker:” New approaches in Triple Negative Breast Cancer”

- August 31-September 3, 24th IPOS World Congress Milano. Round table “Minding the gap in cancer patients’ care trajectory: a multidimensional and multidisciplinary perspective”
- June 30-July 1, Focus on Oncology: from today’s oncology to tomorrow’s oncology”, Lucca scientific responsible
- June 29, 2023 BRCA ROUTE: to structure pathways to manage BRCAm breast cancer treatment, Milan. Invited talk:”clinical case on a patient with HR+/HER2- early breast cancer”
- June 28, 2023 webinar "InFormare Coinvolgere Supportare". Invited talk:”personalized medicine”
- June 27, 2023 “The SPOTLIGHT Program: facciamo luce sul tumore mammario triplo-negativo metastatico”, Milan. Invited talk:”hematologic toxicity of new drugs”
- June 26, 2023 Therapeutic innovation in breast cancer Milano. Invited talk:”updates on metastatic HER2+ breast cancer”
- June 22-23, 2023 NEWS IN ONCOLOGY: FROM USA TO ITALY, Bologna. Invited speaker: “Breast Cancer Highlights”
- June 20, 2023 BREAKING NEWS from ASCO/ESMO 2023: invited speaker ”news in HR+/HER2- breast cancer”
- June 15, 2023 Efficacia e gestione ottimale di trastuzumab deruxtecan nel carcinoma della mammella metastatico HER2+”. Invited speaker: “Efficacia e posizionamento di T-DXd nella malattia HER2+”
- June 14, webinar Highlights from ASCO23. Invited speaker: ”news on chemotherapy and ADCs”
- June 13, 2023 “I nuovi scenari terapeutici del carcinoma mammario triplo-negativo” Napoli
- June 12, 2023 webinar ReLive ASCO 2023: invited speaker ”news in HR+/HER2- breast cancer”
- June 9, 2023 “YBO: Unmet needs in breast cancer care” Genova. Invited talk:the evolving landscape of adjuvant endocrine-based therapy”
- May 31, 2023 Webinar “Oncology’s Wednesdays: HR+HER2- breast cancer: updates from ESMO Breast” Invited talk: “CDK4/6inhibitors, what’s new?”
- May 23-24, 2023 Evolver Milan, Italy: abemaciclib made to be different, the story continues. Round table: the multidisciplinary approach to manage early breast cancer patients”
- May 22, 2023 “Patient Journey- A personalized approach to breast cancer patients”” Invited talk: “(neo)adjuvant immunotherapy in triple-negative breast cancer”
- May 17, 2023 Webinar “Oncology’s Wednesdays: Updates from ESMO Breast. Invited talk: “news in HER2+ breast cancer”
- May 11-13, 2023 ESMO Breast Cancer Congress 2023, Berlin, Germany - invited speaker “clinical implementation of oral SERDs: present and future”
- May 11-13, 2023 ESMO Breast Cancer Congress 2023, Berlin, Germany - invited Discussant in the Mini Oral session 2
- May 7-8, 2023 Faculty Preceptorship BREAST CANCER: Multidisciplinary management, standards of care, therapeutic targets and future perspectives, Milan. Invited talk:” ET and biological agents in advanced HR+/HER2- breast cancer”
- April 26, 2023 European Institute of Oncology, Milan Seminar. Invited talk: ”Drug development progresses in HR+/HER2- metastatic breast cancer”
- April 20-21, 2023 Breast Journal Club, Rome. Moderator:”surgery of the axilla”
- April 14, 2023 Breast Talent 4.0, Rome. Invited speaker:”risk factors and genomic tests in the adjuvant setting”

- April 12-13, 2023 Oncology atelier, Villa Verganti Veronesi, Inveruno (MI). Invited speaker:” Advanced breast cancer: old and new drugs”
- March 30, ESO e-session. Different approaches to BCS and surgical criteria to select patients for NAST. Discussant
- March 30, 2023 Monza “1st BACK FROM INTERNATIONAL CONGRESSES & HOT TOPICS IN ONCOLOGY”, Italy. Invited speaker:”Olaparib and beyond”
- March 25, 2023 MALATTIE DEL METABOLISMO FOSFO-CALCICO. Milano, Italy. Invited speaker: the role of bone-modifying agents in breast cancer”
- March 24, 2023 Santa Margherita Ligure (GE) Italy. "La gestione pratica della paziente con carcinoma mammario hr+/her2-: un percorso condiviso"Invited talk:”Quality of life and adherence”
- March 8, 2023 Women 4 Women, Rome Italy. mBC HER2- and gBRCA mutation
- March 1, 2023 ESMO Webinar in Recurrence Risk in EBC. Invited talk:” Patient-Physician shared decision making and patient support- Case studies for practical tips and tricks”
- February 27, 2023 Sharing experience in Advanced breast cancer
- February 10, 2023 "PD-L1 CPS in TNBC: multicentric shared experience for a test of excellence in pathology" - Milano Italy. Invited talk: “the role of medical oncologist in the test: clinical rationale and practical aspects
- January 31, 2023 time2share - Scientific Exchange Meeting, Milano Italy. Scientific coordinator and moderator
- January 28, 2023 Today’s oncology, Bari Italy. Invited talk “Antibody-drug conjugates in the treatment of breast cancer”
- January 13-14, 2023 Back from San Antonio, Genova Italy. Invited talk “biological news in HER2+ disease”
- January 11, 2023 webinar I mercoledì dell’oncologia. Returning from San Antonio part one. Invited talk: news in systemic disease for luminal-like breast cancer
- December 17, 2022 Bologna: “the pathway of cure for patients with breast cancer “. Invited talk:” the advent of PARP inhibitors”
- December 15, 2022 Roma: “Breast Oncology News & Discussion “. Invited talk:” the definition of high-risk in TNBC”
- November 29-30, 2022 Rome BREAST LIFE 2.0 Journey of patients with mBC. Invited talk:” Evidence supporting the role of talazoparib”
- November 23, 2022 Napoli, REALNESS - inTRODucing the new possible in mTNBC. HR+ disease at diagnosis
- November 18, 2022 Palermo Progetto Amazzone Invited talk:”the cure of breast cancer in 2022” The cure of breast cancer in 2022
- November 12-13, 2022 Milan Preceptorship Breast Cancer Invited talk: “Adjuvant endocrine therapy and CDK 4-6 inhibitors”
- November 10, 2022 Milan Course on analysis and methodology of clinical trials. Tutor at the interactive workshop on clinical trials in oncology
- October 28-29, 2022 Naples Italian Breast Group Annual Meeting. Invited talk:” Updates on early stage Luminal breast cancer”
- October 21-22, 2022 Novara INNOVATORS IN BREAST CANCER. Invited talk:” systemic therapy for HER2+ metastatic breast cancer”
- October 12, 2022 webinar New opportunities and challenges in HER2+ metastatic breast cancer. Invited speaker: Barriers and opportunities to optimize the pathway of patients with brain metastases
- October 8, 2022 CAMPUS BREAST MEETING 2022, Rome. Invited speaker:” Basics of signaling pathways in breast cancer development and progression”

- October 3, 2022 AIOM annual congress, Rome. Life 2 women. How Monaleesa powered a new Italian renaissance. Invited speaker
- October 3, 2022 AIOM annual congress, Rome. Educational session – Treatment of metastatic breast cancer: is the cure possible? Luminal-like breast carcinoma. Invited speaker.
- October 1, 2022 ESMO Preceptorship on breast cancer. Invited talk on “endocrine agents and biologic agents in HR+/HER2- metastatic breast cancer”. Lugano. Switzerland
- September 30, 2022 webinar “Multidisciplinary management of breast cancer”. Invited talk on “news in HR+/HER2- metastatic breast cancer
- September 23-24, 2022 scientific chair “Life2Women”, Milan
- September 20, 2022 invited speaker at “Olympic games in Oncology”, Rome
- September 15, 2022 ESMO Relive, invited talk “news on TNBC”, webinar
- September 15, 2022 webinar “PD-L1 assessment through CPS in TNBC: let’s get started”. Invited talk: “The clinical significance of the test”
- July 6-7, 2022 “EvoLVER – Abemaciclib, progettato per essere diVERso. La storia continua”. Invited talk:” LET’S EVOLVER Abemaciclib, innovation why?”
- June 29-30, 2022 “Research Generators - Widening options in HER2+ metastatic breast cancer". Invited talk:” State of the art and future challenges in HER2+ breast cancer with brain metastases”
- June 14, 2022 Officially licensed Best of ASCO 2022 annual meeting. Invited talk:” The agnostic pathway to approval”
- May 27, 2022 webinar “PIK3CA in breast cancer: strategies to perform the best test to the single patient”. Invited talk:” Therapeutic opportunities in metastatic breast cancer with PIK3CA mutations”
- May 20, 2022 Naples “2022 Cancer Research: from New Orleans to Naples “invited speaker. “New horizons in neoadjuvant immunotherapy”
- May 18, 2022 Rome "BRING IN...THE EXPERTS". Invited speaker “Bring in... the experts in metastatic breast cancer!”
- May 3-5, 2022 ESMO Breast Cancer Congress 2022 (3-5 May), Berlin, Germany - invited Discussant in the Mini Oral session 3
- April 29-30, 2022 Roma "Dive into New Horizons" – Diving into overall survival benefit
- April 26, 2022 O.P.E.R.A. BREAST - “Oncology ProfEssional Remote Academy “- Webinar on breast cancer. Invited talk: “Treatment of metastatic triple negative breast cancer: the role of immunotherapy”
- April 21, 2022 FAD webinar “breast cancer”. Invited talk: “Therapeutic options in HER2+ breast cancer”
- April 21, 2022 Milan “La gestione pratica della paziente con carcinoma mammario HR+/HER2-: un percorso condiviso” - Tavola rotonda multidisciplinare: tumor burden e processo decisionale
- April 6, 2022: FAD webinar “Le nuove prospettive per il carcinoma mammario triplo-negativo e HER2-positivo: il ruolo centrale della Breast Unit”
- April 1, 2022 Naples: Breast Journal Club – l’importanza della ricerca in oncologia: La direzione della ricerca, uno sguardo al futuro
- March 8, 2022 webinar “Women4women”. Invited talk: “real world data with CDK 4/6 inhibitors”
- March 3, 2022 webinar “The management of adverse events in the treatment of TNBC”
- January 15, 2022 Back from San Antonio, Genova Italy. Invited talk “biological news in HER2+ disease”
- December 18, 2021 5th meeting on targeted therapies and immunotherapy in oncology. Invited talk “CDK 4/6 inhibitors in breast cancer”

- December 17, 2021 MBN2021 oncoplastic breast meeting. Invited talk “Management of primary systemic endocrine treatment. Trials-time to surgery-endocrine treatment after partial or no response”
- December 14, 2021 "WEBEXPERT - HIGHLIGHTS SABCS 2021". Invited talk “neoadjuvant/adjuvant HR+/HER2- breast cancer”
- December 9, 2021 invited speaker at Oligometastasis and stereotactic body radiotherapy in the era of systemic targeted therapies and immunotherapy held in Milan, Italy. Invited talk “Combination of radiotherapy and new drugs in oligometastatic breast cancer: the medical oncologist’s point of view”
- November 25, 2021 webinar “What’s new in HER2+ breast cancer”, moderator.
- November 19, 2021 invited speaker at Young oncologists in Immunoncology held virtually. Invited talk “New perspectives: from subtypes to new immune pathways”
- November 12-13, 2021, invited speaker at Breast cancer: evidence and new hopes expert meeting held at Verduno (CN) Italy. Invited talk: “emerging therapies for metastatic breast cancer: looking at the future”
- November 2021 Advanced Breast Cancer Sixth International Consensus Conference (ABC6)– Virtual conference Satellite symposium Beyond the doors of MDT meeting: impact on HR+HER2- breast cancer patients. Real world discussion
- October 2021, webinar Diagnostic of PIK3CA mutational status in breast cancer. Invited talk:” new therapeutic opportunities in advanced ER+/HER2- breast cancer with PIK3CA mutations
- September 25-26, 2021, invited speaker at Breastics24h held online
- September 24, 2021 Invited speaker at Oncology Race “current algorithm in HR+/HER2- metastatic breast cancer
- September 23, 2021 ESMO Relive, invited talk “immunotherapy news”
- September 10-11, 2021 Innovators in Breast Cancer Novara Italy. Invited talk “Questions for the pathologist by a clinician “
- June 29, 2021 Breast talk. De novo metastatic disease case presentation
- June 29, 2021 Breast Cancer Retreat 2021. Invited talk: “Overview of CDK 4/6 inhibitors in Luminal MBC”
- June 25, 2021 Pfizer Symposium at “Medisprof’s Best of ASCO 2021 Conference” (Romanian Best of ASCO). Invited talk:” From Clinical Trials to Real-World Effectiveness: Charting a new standard in HR+/HER2- ABC”
- June 23, 2021 BConnect – Virtual Connected Education VCoE; Verzenio case presentation
- June 22, 2021 evoluzione del trattamento della paziente con carcinoma mammario metastatico HR+/HER2-. Dall’Mbc all’adiuvante.

- June 15, 2021 YBO: Unmet need in breast cancer care. Invited talk: “Selecting the best immunotherapy regimen in breast cancer”
- May 27, 2021 virtual lecture for Maltese oncologists: “overall survival data and latest updates in CDK 4/6 inhibitors”
- May 26, 2021 AIOM webinar “Therapeutic strategy in HR+/HER2- mBC”. Invited talk: How to select patients
- May 21, 2021 Women’s Outline: from clinical outcomes to patients profiles. How to select CDK4/6 inhibitor treatment
- May 10, 2021 CGP ROADSHOW 2021 breast cancer
- May 8, 2021 ESMO Breast Cancer Virtual Congress 2021. Invited Discussant in the Proffered Paper session 2
- May 5, 2021 AIOM webinar “Immunotherapy in breast cancer”. Invited talk: Immunotherapy in breast cancer: clinical trials’ results
- April 19, 2021 ESO e-session Early breast cancer: Adjuvant versus neoadjuvant chemotherapy
- March 31, 2021 webinar “Webreast: conversation on abemaciclib”.
- March 26, 2021 webinar “Together is better: update on HR+/HER2- breast cancer”. Invited talk: Evolution in the treatment of metastatic HR+/HER2- breast cancer
- March 25, 2021 moderator web conference “HR+/HER2- breast cancer: new paradigms”
- March 23, 2021 Real world data in metastatic breast cancer between daily practice, research and regulatory. Invited talk: Real world data in HER2+ metastatic breast cancer
- March 10, 2021 webinar: the role of communication in breast cancer
- March 8, 2021 webinar women for women: The use of CDK 4/6 inhibitors in breast cancer patients with co-morbidities

- March 1, 2021 Webinar PIK3CA mutation and breast cancer. Talk: biologic rational for the use of PI3K inhibitors
- January 16, 2021 Back From San Antonio: “New biologic findings in HER2+ breast cancer”
- December 10, 2020. The Latvian association of oncologists and breast diseases. Lecture: Recent developments in the diagnostic and treatment of breast cancer
- November 18, 2020. YO-IO: Young Oncologists in immunoncology. Talk: State-of-art: immunotherapy in breast cancer. From neoadjuvant to first line.
- November 16, 2020. Special breast 2020, annual meeting on HR+/HER2- metastatic breast cancer. Talk: Pathology framework, therapeutic strategies and positioning of choices
- November 2020, FAD asincrona. Riunione annual Gruppo Italiano Mammella (GIM). Malattia operabile: stato dell'arte tumori Luminali
- October 31, 2020 XXII Congresso Nazionale AIOM 2020. CDK4/6i: dall’evoluzione nel mBC alla rivoluzione nell’eBC. L’evoluzione continua nel trattamento del mBC HR+/HER2-
- October 31, 2020 XXII Congresso Nazionale AIOM 2020. Satellite symposium: Palbociclib: il farmaco che ha tracciato un nuovo percorso di cura per le pazienti con mBC HR+/HER2-. Evidenze di efficacia che hanno tracciato un percorso
- October 23, 2020 ESSO 2020 Virtual. “Neoadjuvant chemotherapy in the era of immunotherapy: the future is bright”
- September 24, 2020 Webinar ReLive ESMO 2020
- September 24, 2020 W4O virtual mentorship session “Optimal time management in paper and grant writing”
- September 7-8, 2020 digital event Young to Young 2020 L’oncologia di domani
- June 23, 2020 Webinar Breast Journal Club “update from ESMO”
- June 18, 2020 VCOE – novità nella Gestione della paziente con carcinoma mammario”

- June 3, 2020 Webinar “Caring for cancer patients during the COVID-19 pandemic; experiences and learnings from a red zone”
- May 24, 2020 ESMO Breast Cancer Virtual Meeting: “Managing side effects of immunotherapy”
- April 22, 2020 Webinar on “Management of cancer patients in COVID era”
- February 13, 2020 San Antonio & Beyond, Rimini – Italy: “Immune checkpoint inhibitors in breast cancer”
- January 10-11, 2020 Back From San Antonio. Genova – Italy: “New biologic findings in HER2+ breast cancer”
- November 29, 2019 Molecular Pathology in interventional radiology - Monza, Italy: “NGS in breast cancer”
- November 16, 2019 Breast Cancer Retreat - Naples, Italy: The role of CDK 4/6 inhibitors in clinical practice
- October 26, 2019 AIOM annual meeting – Rome, Italy: oral presentation “Tumor Infiltrating Lymphocytes (TILs) in ER+/HER2- breast cancer”
- October 18, 2019 W4O post-ESMO meeting – Naples, Italy: Breast cancer updates
- October 11, 2019 SAMO Interdisciplinary Workshop on Breast Tumors- Lucerne, Switzerland: Recent Developments in Metastatic Breast Cancer (Immunotherapy)
- October 4-5, 2019 AIOM Breast cancer, Rome – Italy: Treatment of metastatic HER2-positive breast cancer
- September 28, 2019 ESMO annual meeting, Barcelona – Spain: poster discussion, breast cancer early stage
- September 28, 2019 ESMO annual meeting, Barcelona – Spain: YO boxing session: De-escalation in early HER2+ breast cancer

- September 20, 2019 the breast unit in Oncology, Bergamo Italy: metastatic triple negative breast cancer
- September 12-13 2019 Going beyond in oncology Naples, Italy
- June 14-15 2019 AIOM REVIEW: FROM CHICAGO TO VERONA Verona, Italy: Breast Cancer Poster Review
- May 18-19, NAPLES LATE SPRING INTERACTIVE COURSE 2019, Naples-Italy: “Systemic treatment and metastatic disease: Luminal breast cancer”
- May 18-19, NAPLES LATE SPRING INTERACTIVE COURSE 2019, Naples-Italy: “Systemic treatment and metastatic disease: HER2+ breast cancer”
- May 4, 2019 ESMO Breast Cancer, Berlin – Germany: oral presenter “TILs in ER+/HER2- breast cancer”
- May 4, 2019 ESMO Breast Cancer, Berlin – Germany: invited speaker “Immune therapy as a generalistic approach”
- May 3, 2019 ESMO Breast Cancer, Berlin – Germany: ESMO WEBINAR Enhancing Immunogenicity in “Immune Excluded” or “Immune Desert” Breast Cancers
- May 3, 2019 ESMO Breast Cancer, Berlin – Germany: session coordinator “Vesalius Talk: developing effective leadership skills”
- March 19-20, 2019 DIVE Into Breast Care, Milano-Italy:” CDK4/6 inhibitors in postmenopausal women with metastatic breast cancer”
- February 21-22, 2019 FOCUS SUL CARCINOMA MAMMARIO. Udine –Italy: ”Top-five from ASCO/ESMO”
- January 11-12, 2019 Back From San Antonio. Genova – Italy: “New biologic findings in HER2+ breast cancer”

- November 28, 2018 1st European Course for MSd in training GOING BEYOND IN ONCOLOGY. Milano –Italy:” Integration of new drugs and old drugs into your clinical practice”
- November 9, 2018 17th Stage in Medical Oncology. Taormina – Italy: “Breaking news in ER+ breast cancer”
- October 27, 2018 Innovators in Breast Cancer. Baveno-Italy: “Round Table: The future of Breast Cancer Research: Young Oncologists Corner”
- October 26, 2018 Carcinoma mammario i traguardi raggiunti e le nuove sfide. Roma-Italy: “Terapia sistemica adiuvante: quando e quale?”
- October 13, 2018 Novità in carcinoma mammario, Bari-Italy: “Pazienti “triple positive”: solo ormonoterapia e anti HER-2?”
- June 26, 2018 IL PERCORSO CLINICO-ASSISTENZIALE PER LE DONNE CON TUMORE DELLA MAMMELLA - IX Edizione, Bologna-Italy: “La chemioterapia nel carcinoma mammario metastatico dopo antracicline e taxani in adiuvante: strategia nel 2018
- June 16, 2018 ESMO Leaders Generation Programme. Round Table Discussion in the session on W4O: Women in Oncology. Lugano- Switzerland
- June 16, 2018 invited talk at AIOM post ASCO, Milano- Italy: “ASCO Poster Review”
- May 5-6, 2018 invited talk at Etna Late Spring Meeting 2018 Downsizing surgical treatment with systemic therapies. Giarre (Catania) – Italy: “primary systemic treatment: the very first therapeutic tool? Results from trials”.
- April 14-15, 2018 poster discussant at Okayama TR meeting. Okayama, Japan
- March 24, 2018 chair at CANOA Project. “Breast Cancere: which news in 2018? How to interpret a clinical trial”. Ospedaletto di Pescantina (VR) Italy

- March 8, 2018 invited talk at Women for Women – , Rome Italy: “unmet need in metastatic breast cancer”
- February 10, 2018 invited talk at BREASTorming – dalle evidenze alla pratica clinica nel BC HER2+, Napoli Italy: “Cosa dicono e non dicono le linee guida nel mBC HER2+”
- February 8, 2018 invited talk at PALMARES – Palbociclib il primato dell’innovazione nel mBC, Roma Italy: “Palbociclib in HER2+ disease”
- January 12, 2018 award and invited talk at "Back from San Antonio", Genova Italy: “A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer”
- December 14, 2017 invited speaker at the MBN 2017 Oncoplastic Breast Meeting, Milano Italy: “Primary systemic therapies”
- September 10, 2017 invited speaker at the 2017 ESMO annual meeting, Madrid Spain: ESMO Clinical Practice Guidelines –“Patient with metastatic breast cancer: Sequence of therapies, case presentation”
- September 9, 2017 oral presentation at the 2017 ESMO annual meeting, Madrid Spain: “A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy”
- June 23, 2017 invited speaker at the 2017 Umberto Veronesi MBCC, Milano Italy: “Targeting DNA repair”
- June 22, 2017 invited speaker at ESO Masterclass in Oncology Basics for Beginners Cambridge, UK: “Breast cancer: Outline of management”
- June 22, 2017 invited speaker at ESO Masterclass in Oncology Basics for Beginners Cambridge, UK: “Abnormal CXR in a young female”

- May 26, 2017 invited speaker at the “IL TRATTAMENTO DELLA PAZIENTE ANZIANA CON CARCINOMA MAMMARIO” Milano, Italy: therapeutic algorithm in elderly patients with Her2+ mBC
- May 12th, 2017 invited speaker at 8th “Il Percorso Clinico-assistenziale per le donne con tumore della mammella” Bologna, Italy: Immunotherapy
- March 21-23, 2017 invited speaker at 28th International Congress on Anti-Cancer Treatment (ICACT 2017) Paris, France: Genomic predictors of sensitivity to anti-PD1
- March 15, 2017 St Gallen breast cancer conference in Vienna, Austria: Satellite symposium e cancer The coming of age for CDK 4/6 inhibitors, invited speaker on Clinical trial results: the benefits, side effects and costs.
- November 16-17, 2016. Madrid, Spain: Everyday is precious MBC summit
- October 17, 2016 invited speaker at EONS Dublin, Ireland: CDK 4/6 inhibitors: clinical data on breast trials.
- July 7-9, 2016 panelist at Harvard CME course Breast Cancer: New Horizons, Current Controversies, Boston USA.
- June 16-18, 2016 invited speaker at ESSO advanced course on oncoplastic breast surgery. Budapest, Hungary.
- April 2016, invited speaker at “Giornate Salentine in Oncologia” Regional Meeting, Lecce Italy: from gene expression profiling to immunity and microenvironment in breast cancer
- March 2016, invited speaker for European Society of Surgical Oncology Workshop at 10th European Breast Cancer Conference (EBCC-10), Amsterdam, The Netherlands: Value of Tumor-Infiltrating Lymphocytes in Neoadjuvant Treatment: Involvement in Prognosis and Pathologic Complete Response (pCR)

- December 2015, invited speaker at Immuno-Oncology Regional Meeting, Salerno Italy: The role of immunotherapy in the Breast Cancer and Focus on TILs in the Breast Cancer
- November 2015, invited speaker at HER2 + Breast Cancer: Challenges and Unanswered questions. BREAST CANCER PRECEPTORSHIP PROGRAMME. Medical Oncology Department. Ramon y Cajal University Hospital, Madrid, Spain
- October 2014, invited speaker at ESSO, Liverpool UK: Debate: Which is Superior Neoadjuvant Therapy: Endocrine or Systemic Chemotherapy? Pro neoadjuvant chemotherapy
- September 2014, invited speaker at ESMO, Madrid Spain: Contribution of immune response to anti-tumour effect of chemotherapy.
- June 2014 invited speaker at MBCC, Milan Italy: Immunomarkers in early triple negative breast cancer.
- June 2014 invited seminar at MDACC, Houston Texas: the role of tumor infiltrating lymphocytes in breast cancer.
- May 2014 selected abstract for oral presentation at IMPAKT. Generation of mouse models for the identification of new driver pathways of drug resistance in human breast cancer (BC)
- March 2014 Invited talk: Presentation of a Flims' protocol. Flims Alumni Club Session – Research Advances and Current Practice in the Management of Breast Cancer. EBCC9, Glasgow Scotland.
- January 2014 Invited talk: “METASTASES: faut-il les biopsier?”. Biennale Monégasque de Cancérologie, Cours Francophone d'Oncologie. Monaco
- June 2013 Invited talk: “Chemotherapy benefit in Luminal breast cancer”. Breast Cancer Progress and Controversies. Naples, Italy.
- “The discrepancy between high pathological complete response (pCR) rate and low breast conserving surgery (BCS) following neoadjuvant therapy: analysis from the NeoALTTO trial

(BIG 1-06)”: abstract accepted for Proffered Paper (Oral) presentation during the ESMO 2012 Congress, 28 September - 2 October, Vienna, Austria.

- 19-02-2011 Abstract accepted for oral presentation during BSMO (Belgian Society of Medical Oncology), Brussels, Belgium “More advanced stage Luminal A early breast cancers show distinct gene expression patterns associated with worse clinical outcome.
- April 2010 Invited talk: “Biologics in adjuvant setting: where are we?” in: Winter Academy of Oncology: Early breast cancer, Pontresina, Switzerland.

COURSES:

- 2016 ESMO Leaders Generation Programme - Lugano – 27-29 June and 10-12 September 2016
- Breast Cancer Academy – Module 1. Barcelone, Spain 14-15 May 2015. Module 2. Brussels, Belgium 3-4 September 2015. Module 3. Paris, France 19-20 May 2016.
- ECCO-AACR-EORTC-ESMO Workshop "Methods in clinical cancer research". Flims, Switzerland — 18 - 24 June 2011
- Pre-IMPAKT Training Course. Brussels, Belgium 4-5 May 2011.
- EORTC Course “Methodology of cancer clinical trials: the next generation”. Brussels, Belgium 7-10 September 2010.
- Pre-IMPAKT Training Course. Brussels, Belgium 5-6 May 2010.
- The Vito Distante Project in Breast Cancer Clinical Research. Tuscany, Italy 30 August- 2 September 2009
- Pre-IMPAKT Training Course. Brussels, Belgium 6-7 May 2009.

LIST OF PUBLICATIONS:

1. Giugliano F, De Angelis C, Pistilli B, Viale G, Bianchini G, Giuliano M, Malorni L, Taurelli Salimbeni B, Esposito A, Giordano A, Yap TA, Curigliano G, **Criscitiello C**. Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies. *Cancer Treat Rev*. 2025 Jun 14;139:102980. doi: 10.1016/j.ctrv.2025.102980. Online ahead of print. PMID: 40544690
2. Miglietta F, Razeti MG, Caltavituoro A, Dri A, Valenza C, Bianchini G, Biganzoli L, Botticelli A, Caruso M, Cinieri S, **Criscitiello C**, De Angelis C, De Laurentis M, Del Mastro L, De Placido S, Del Re M, Dieci MV, Fabi A, Generali D, Gennari A, Gerratana L, Giuliano M, Lambertini M, Malapelle U, Malorni L, Meattini I, Paris I, Pruneri G, Zamagni C, Zambelli A, Bidard FC, Guarneri V, Puglisi F, Curigliano G, Arpino G. The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report. *Crit Rev Oncol Hematol*. 2025 Jun 6;213:104793. doi: 10.1016/j.critrevonc.2025.104793. PMID: 40484157
3. Buonaiuto R, Botticelli A, **Criscitiello C**, Dieci MV, Fusco N, Gerratana L, Lambertini M, Malapelle U, Malorni L, De Angelis C. Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression. *Cancer Treat Rev*. 2025 May 27;138:102972. doi: 10.1016/j.ctrv.2025.102972. PMID: 40450825
4. Scafetta R, Donato M, Gullotta C, Guarino A, Fiore C, Sisca L, Speziale E, Troiano R, Foderaro S, Ricozzi V, Iuliani M, Simonetti S, Cavaliere S, Cortellini A, Botticelli A, Scagnoli S, Pisegna S, **Criscitiello C**, Pedersini R, Sposetti C, Tiberi E, D'Auria G, Vergati M, Mazzotta M, Caputo R, Verrazzo A, Rossino MG, Domati F, Piombino C, Di Lisa FS, Filomeno L, Arcuri T, Puce F, Riva F, Palleschi M, Sirico M, Piras M, Stucci LS, De Lisi D, Orsaria P, Ippolito E, Ramella S, Visani L, Bertini N, Bonaparte I, Gori S, Rossi L, Meattini I, Tagliaferri B, Caffo O, Portarena I, Irelli A, Cretella E, Porta C, Bianchini G, Fabbri A, De Giorgi U, Vici P, Toss A, Garrone O, De Laurentiis M, Villa F, Berardi R, Minelli M, Vernieri C, Curigliano G, Vincenzi B, Tonini G, Santini D, Pantano F. Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors. *Breast*. 2025 May 15;82:104502. doi: 10.1016/j.breast.2025.104502. PMID: 40424680
5. Venetis K, Cursano G, Scafetta R, Giachetti PPMB, Concardi A, De Camilli E, D'Ercole M, Mane E, Frascarelli C, Marra A, Gandini S, Pepe F, Scagnoli S, Rossi SM, Troiano R, Speziale E, De Angelis C, Troncone G, Malapelle U, Perrone G, Botticelli A, Viale G, Curigliano G, Guerini Rocco E, **Criscitiello C**, Fusco N. ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy. *Breast Cancer Res*. 2025 May 14;27(1):79. doi: 10.1186/s13058-025-02020-x. PMID: 40369610
6. Valsecchi AA, Pisegna S, Antonuzzo A, Arpino G, Bianchini G, Biganzoli L, Colloca GF, **Criscitiello C**, Danesi R, Fabi A, Giusti R, Pau L, Di Maio M, Santini D. Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan. *Oncologist*. 2025 May 8;30(5):oyaf088. doi: 10.1093/oncolo/oyaf088. PMID: 40366333
7. Taurelli Salimbeni B, Giudici F, Pescia C, Berton Giachetti PPM, Scafetta R, Zagami P, Marra A, Trapani D, Esposito A, Scagnoli S, Cerbelli B, Botticelli A, Munzone E, Fusco N, **Criscitiello C**, Curigliano G. Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment. *NPJ Breast Cancer*. 2025 May 10;11(1):41. doi: 10.1038/s41523-025-00760-9. PMID: 40346114

8. Giugliano F, Giordano E, Gilardi L, Salimbeni BT, Zagami P, Esposito A, Marra A, Trapani D, Berton Giachetti PPM, Malagutti B, Henry T, Deandreis D, Curigliano G, Ceci F, **Criscitiello C**. Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology. *Cancer Treat Rev*. 2025 May;136:102940. doi: 10.1016/j.ctrv.2025.102940. Epub 2025 Apr 8. PMID: 40228448
9. Provenzano L, Dieci MV, Curigliano G, Giuliano M, Botticelli A, Lambertini M, Rizzo G, Pedersini R, Sirico M, La Verde N, Gennari A, Zambelli A, Toss A, Piras M, Giordano M, Tagliaferri B, Generali D, Sartori D, Miliziano D, Menichetti A, Ligorio F, Zurlo C, Griguolo G, Berton Giachetti PP, Faso V, Corti C, Chiappe E, Scagnoli S, Pisegna S, Capasso C, De Angelis C, Arpino G, **Criscitiello C**, Guarneri V, Pruneri G, Mariani L, Vernieri C; PALMARES-2 study group. Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study. *Ann Oncol*. 2025 Apr 7:S0923-7534(25)00134-6. doi: 10.1016/j.annonc.2025.03.023. PMID: 40204155
10. Boscolo Bielo L, Crimini E, Repetto M, Barberis M, Battaiotto E, Katrini J, Martino E, Gaudio G, Lombardi M, Zanzottera C, Aurilio G, Belli C, Zhan Y, Fuorivia V, Marsicano RM, Etessami JD, Zagami P, Marra A, Trapani D, Taurelli Salimbeni B, **Criscitiello C**, Ciardiello D, Lavinia B, Gervaso L, Cella CA, Spada F, Zampino MG, Fusco N, Fazio N, Guerini Rocco E, Curigliano G. Molecular tumour board in gastrointestinal cancers. *ESMO Open*. 2025 Mar 19;10(4):104510. doi: 10.1016/j.esmoop.2025.104510. PMID: 40112698
11. Berton Giachetti PPM, Carnevale Schianca A, Trapani D, Marra A, Toss A, Marchiò C, Dieci MV, Gentilini OD, **Criscitiello C**, Kalinsky K, Sparano JA, Curigliano G. Current controversies in the use of Oncotype DX in early breast cancer. *Cancer Treat Rev*. 2025 Jan 16;135:102887. doi: 10.1016/j.ctrv.2025.102887. PMID: 40048856
12. Lambertini M, Blondeaux E, Tomasello LM, Agostinetto E, Hamy AS, Kim HJ, Franzoi MA, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore HCF, Partridge AH, Phillips KA, Toss A, Rousset-Jablonski C, **Criscitiello C**, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg KA, Duhoux FP, Livraghi L, Bruzzone M, Boni L, Balmaña J. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. *J Clin Oncol*. 2025 Feb 24;JCO2401334. doi: 10.1200/JCO-24-01334. PMID: 39993249
13. Berton Giachetti PPM, Morganti S, Gandini S, Giudici F, Marra A, Nicolò E, Zattarin E, Corti C, Boldrini L, Verrazzo A, Sposetti C, Razeti MG, Carnevale Schianca A, Scafetta R, Taurelli Salimbeni B, Esposito A, Zagami P, Trapani D, Malagutti B, Caputo R, Vernieri C, Munzone E, Scagnoli S, Botticelli A, Lambertini M, Giuliano M, De Laurentiis M, Viale G, Bianchini G, Curigliano G, De Angelis C, **Criscitiello C**. Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. *JAMA Netw Open*. 2025 Feb 3;8(2):e2461067. doi: 10.1001/jamanetworkopen.2024.61067. PMID: 39982725
14. Venetis K, Frascarelli C, Bielo LB, Cursano G, Adorisio R, Ivanova M, Mane E, Peruzzo V, Concardi A, Negrelli M, D'Ercole M, Porta FM, Zhan Y, Marra A, Trapani D, **Criscitiello C**, Curigliano G, Guerini-Rocco E, Fusco N. Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact. *Eur J Cancer*. 2025 Jan 13;217:115233. doi: 10.1016/j.ejca.2025.115233. PMID: 39827722
15. Zagami P, Esposito A, Taurelli Salimbeni B, Berton Giachetti PPM, Scafetta R, Lambertini M, Di Maio M, Curigliano G, **Criscitiello C**, Cinieri S. Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer. *Breast*. 2025 Jan 10;79:103875. doi: 10.1016/j.breast.2025.103875. PMID: 39826385

16. Scafetta R, Zagami P, Del Re M, **Criscitiello C**, Marra A, Curigliano G. Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences. *Breast Cancer Res Treat.* 2025 Jan 8. doi: 10.1007/s10549-024-07595-1. PMID: 39776334
17. Esposito A, Crimini E, **Criscitiello C**, Belli C, Scafetta R, Scalia R, Castellano G, Giordano E, Katrini J, Ascione L, Boscolo Bielo L, Repetto M, Marra A, Trapani D, Varano GM, Maiettini D, Della Vigna P, Orsi F, Guerini Rocco E, Fusco N, Curigliano G. The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit. *Cancers (Basel).* 2024 Dec 20;16(24):4252. doi: 10.3390/cancers16244252. PMID: 39766151
18. Frascarelli C, Venetis K, Marra A, Mane E, Ivanova M, Cursano G, Porta FM, Concardi A, Ceol AGM, Farina A, **Criscitiello C**, Curigliano G, Guerini-Rocco E, Fusco N. Deep learning algorithm on H&E whole slide images to characterize *TP53* alterations frequency and spatial distribution in breast cancer. *Comput Struct Biotechnol J.* 2024 Nov 26;23:4252-4259. doi: 10.1016/j.csbj.2024.11.037. eCollection 2024 Dec. PMID: 39678362
19. Milano M, Valenza C, Ferrari A, Gandini S, Trapani D, Santoro C, Battaiotto E, Carnevale Schianca A, Giordano E, Katrini J, Castellano G, Taurelli Salimbeni B, Leonardi MC, Dicuonzo S, **Criscitiello C**, Bianco N, Dellapasqua S, Munzone E, Curigliano G, Colleoni M, Jereczek-Fossa BA. Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer. *Eur J Cancer.* 2024 Dec 6;215:115164. doi: 10.1016/j.ejca.2024.115164. PMID: 39662096
20. Bartsch R, Cameron D, Ciruelos E, **Criscitiello C**, Curigliano G, Duhoux FP, Foukakis T, Gligorov J, Harbeck N, LeVasseur N, Okines A, Penault-Llorca F, Müller V. Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer. *Cancer Treat Rev.* 2024 Nov 14;132:102853. doi: 10.1016/j.ctrv.2024.102853. PMID: 39580869
21. Corti C, Binboğa Kurt B, Koca B, Rahman T, Conforti F, Pala L, Bianchini G, **Criscitiello C**, Curigliano G, Garrido-Castro AC, Kabraji SK, Waks AG, Mittendorf EA, Tolaney SM. Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy. *Cancer Treat Rev.* 2024 Nov 13;132:102852. doi: 10.1016/j.ctrv.2024.102852. Online ahead of print. PMID: 39571402
22. Valenza C, Trapani D, Zagami P, Antonarelli G, Boscolo Bielo L, Nicolò E, Ribeiro JM, Guidi L, Reduzzi C, Spotti M, Adamoli L, Cortès J, Pistilli B, Tolaney SM, Ueno N, Layman RM, Cristofanilli M, Carey LA, Munzone E, **Criscitiello C**, Lynce F, Woodward WA, Curigliano G. Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study. *Eur J Cancer.* 2024 Oct 28;213:115097. doi: 10.1016/j.ejca.2024.115097. Online ahead of print. PMID: 39486164
23. Boscolo Bielo L, Guerini Rocco E, Crimini E, Repetto M, Lombardi M, Zanzottera C, Aurilio G, Barberis M, Belli C, Zhan Y, Battaiotto E, Katrini J, Marsicano R, Zagami P, Taurelli Salimbeni B, Esposito A, Trapani D, **Criscitiello C**, Fusco N, Marra A, Curigliano G. Molecular tumor board in patients with metastatic breast cancer. *Breast Cancer Res Treat.* 2024 Oct 30. doi: 10.1007/s10549-024-07535-z. Online ahead of print. PMID: 39476312
24. Gori S, De Rose F, Ferro A, Fabi A, Angiolini C, Azzarello G, Cancian M, Cinquini M, Arecco L, Aristei C, Bernardi D, Biganzoli L, Cariello A, Cortesi L, Cretella E, **Criscitiello C**, De Giorgi U, Carmen De Santis M, Deledda G, Dessena M, Donati S, Dri A, Ferretti G, Foglietta J, Franceschini D, Franco P, Schirone A, Generali D, Gianni L, Giordani S, Grandi G, Cristina Leonardi M, Magno S, Malorni L, Mantoan C, Martorana F, Meattini I, Meduri B, Merlini L, Miglietta F, Modena A, Nicolis F, Palumbo I, Panizza P, Angela Rovera F,

- Salvini P, Santoro A, Taffurelli M, Toss A, Tralongo P, Turazza M, Valerio M, Verzè M, Vici P, Zamagni C, Curigliano G, Pappagallo G, Zambelli A; Italian Association of Multidisciplinary Oncology Groups (AIGOM). Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project. *Cancer Treat Rev.* 2024 Oct 5;131:102832. doi: 10.1016/j.ctrv.2024.102832. Online ahead of print.PMID: 39437511
25. Boscolo Bielo L, Guerini Rocco E, Trapani D, Zagami P, Taurelli Salimbeni B, Esposito A, Belli C, Crimini E, Venetis K, Munzone E, Fusco N, Criscitiello C, Marra A, Curigliano G. Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations. *ESMO Open.* 2024 Oct;9(10):103731. doi: 10.1016/j.esmoop.2024.103731. Epub 2024 Oct 1.PMID: 39357123
 26. Barclay NL, Burn E, Delmestri A, Duarte-Salles T, Golozar A, Man WY, Tan EH, Tietzova I; OPTIMA Consortium; Prieto-Alhambra D, Newby D. Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021. *Sci Rep.* 2024 Aug 17;14(1):19069. doi: 10.1038/s41598-024-69006-1.PMID: 39153995
 27. Massa D, Vernieri C, Nicolè L, **Criscitiello C**, Boissière-Michot F, Guiu S, Bobrie A, Griguolo G, Miglietta F, Vingiani A, Lobefaro R, Taurelli Salimbeni B, Pinato C, Schiavi F, Brich S, Pescia C, Fusco N, Pruneri G, Fassan M, Curigliano G, Guarneri V, Jacot W, Dieci MV. Immune and Gene-expression Profiling in Estrogen Receptor Low and Negative Early Breast Cancer. *J Natl Cancer Inst.* 2024 Jul 31:djae178. doi: 10.1093/jnci/djae178. Online ahead of print.PMID: 39083015
 28. Mariani M, Viale G, Galbardi B, Licata L, Bosi C, Dugo M, Notini G, Naldini MM, Callari M, **Criscitiello C**, Pusztai L, Bianchini G. Completion Rate and Positive Results Reporting Among Immunotherapy Trials in Breast Cancer, 2004-2023. *JAMA Netw Open.* 2024 Jul 1;7(7):e2423390. doi: 10.1001/jamanetworkopen.2024.23390.PMID: 39028669
 29. Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, de Giorgi U, Cortesi E, Fabbri A, Fabi A, Paris I, Orlandi A, Curigliano G, **Criscitiello C**, Garrone O, Tomasello G, D'Auria G, Vici P, Ricevuto E, Domati F, Piombino C, Parola S, Scafetta R, Cirillo A, Taurelli Salimbeni B, Di Lisa FS, Strigari L, Preissner R, Simmaco M, Santini D, Marchetti P, Botticelli A. Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study. *NPJ Breast Cancer.* 2024 Jul 17;10(1):58. doi: 10.1038/s41523-024-00657-z.PMID: 39019916
 30. Guerini-Rocco E, Venetis K, Cursano G, Mane E, Frascarelli C, Pepe F, Negrelli M, Olmeda E, Vacirca D, Ranghiero A, Trapani D, **Criscitiello C**, Curigliano G, Rolfo C, Malapelle U, Fusco N. Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer. *Crit Rev Oncol Hematol.* 2024 Jun 23;201:104427. doi: 10.1016/j.critrevonc.2024.104427. PMID: 38917944
 31. Nicolò E, Gandini S, Giugliano F, Uliano J, D'Ecclesiis O, Morganti S, Ferraro E, Trapani D, Tarantino P, Zagami P, Boldrini L, Caramella I, Carnevale Schianca A, Cristofanilli M, Locatelli MA, Esposito A, Belli C, Minchella I, **Criscitiello C**, Marra A, Curigliano G. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials. *Eur J Cancer.* 2024 Jun 17;207:114181. doi: 10.1016/j.ejca.2024.114181. PMID: 38909537
 32. Corso G, Fusco N, Guerini-Rocco E, Leonardi MC, **Criscitiello C**, Zagami P, Nicolò E, Mazzarol G, La Vecchia C, Pesapane F, Zanzottera C, Tarantino P, Petitto S, Bianchi B, Massari G, Boato A, Sibilio A, Polizzi A, Curigliano G, De Scalzi AM, Lauria F, Bonanni B, Marabelli M, Rotili A, Nicosia L, Albini A, Calvello M, Mukhtar RA, Robson ME, Sacchini V, Rennert G, Galimberti V, Veronesi P, Magnoni F. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment. *Semin Oncol.* 2024 May 20:S0093-7754(24)00038-1. doi: 10.1053/j.seminoncol.2024.05.001. Online ahead of print.PMID: 38897820

33. Koukoutzeli C, Trapani D, Ascione L, Kotteas E, Marra A, **Criscitiello C**, Curigliano G. Use of Antibody-Drug Conjugates in the Early Setting of Breast Cancer. *Clin Med Insights Oncol.* 2024 Jun 17;18:11795549241260418. doi: 10.1177/11795549241260418. eCollection 2024.PMID: 38894701
34. Ivanova M, Pescia C, Trapani D, Venetis K, Frascarelli C, Mane E, Cursano G, Sajjadi E, Scatena C, Cerbelli B, d'Amati G, Porta FM, Guerini-Rocco E, **Criscitiello C**, Curigliano G, Fusco N. Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence. *Cancers (Basel).* 2024 May 23;16(11):1981. doi: 10.3390/cancers16111981.PMID: 38893102
35. Venetis K, Pescia C, Cursano G, Frascarelli C, Mane E, De Camilli E, Munzone E, Dellapasqua S, **Criscitiello C**, Curigliano G, Guerini Rocco E, Fusco N. The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy. *Int J Mol Sci.* 2024 May 24;25(11):5717. doi: 10.3390/ijms25115717.PMID: 38891906
36. Boscolo Bielo L, Trapani D, Nicolò E, Valenza C, Guidi L, Belli C, Kotteas E, Marra A, Prat A, Fusco N, **Criscitiello C**, Burstein HJ, Curigliano G. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer. *Cancer Treat Rev.* 2024
37. Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, **Criscitiello C**, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, Michiels S; International Immuno-Oncology Biomarker Working Group. Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. *JAMA.* 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056.PMID: 38563834
38. Morganti S, Marra A, De Angelis C, Toss A, Licata L, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Esposito A, Giordano A, Bianchini G, Garber JE, Curigliano G, Lynce F, **Criscitiello C**. PARP Inhibitors for Breast Cancer Treatment: A Review. *JAMA Oncol.* 2024 Mar 21. doi: 10.1001/jamaoncol.2023.7322. PMID: 38512229
39. Migliaccio I, Romagnoli D, Galardi F, De Luca F, Biagioni C, Curigliano G, **Criscitiello C**, Minisini AM, Moretti E, Risi E, Guarducci C, Nardone A, Biganzoli L, Benelli M, Malorni L. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TReND Trial. *JCO Precis Oncol.* 2024 Feb;8:e2300285. doi: 10.1200/PO.23.00285.PMID: 38427931
40. Ivanova M, Frascarelli C, Cerbelli B, Pignataro MG, Pernazza A, Venetis K, Sajjadi E, **Criscitiello C**, Curigliano G, Guerini-Rocco E, Graziano P, Martini M, d'Amati G, Fusco N. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores. *Hum Pathol.* 2024 Jan 24:S0046-8177(24)00008-X. doi: 10.1016/j.humpath.2024.01.008. PMID: 38278450
41. Marchiò C, **Criscitiello C**, Scatena C, Santinelli A, Graziano P, Malapelle U, Cursano G, Venetis K, Fanelli GN, Pepe F, Berrino E, Angelis C, Perrone G, Curigliano G, Fusco N. Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer. *Pathologica.* 2023 Dec;115(6):292-301. doi: 10.32074/1591-951X-942.PMID: 38180137
42. Cursano G, Frigo E, Sajjadi E, Ivanova M, Venetis K, Guerini-Rocco E, **Criscitiello C**, Curigliano G, Fusco N. Trop-2 as an Actionable Biomarker in Breast Cancer. *Curr Genomics.* 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233.PMID: 38178982
43. Cobanaj M, Corti C, Dee EC, McCullum L, Boldrini L, Schlam I, Tolaney SM, Celi LA, Curigliano G, **Criscitiello C**. Advancing equitable and personalized cancer care: Novel

- applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow. *Eur J Cancer*. 2023 Dec 19;198:113504. doi: 10.1016/j.ejca.2023.113504. PMID: 38141549
44. Lambertini M, Blondeaux E, Agostinetto E, Hamy AS, Kim HJ, Di Meglio A, Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J, Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C, Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA, Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C, Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L, Partridge AH; BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study. *JAMA*. 2023 Dec 7:e2325463. doi: 10.1001/jama.2023.25463. Online ahead of print. PMID: 38059899
 45. Zagami P, Trapani D, Nicolò E, Corti C, Valenza C, **Criscitiello C**, Curigliano G, Carey LA. Cardiotoxicity of Agents Used in Patients With Breast Cancer. *JCO Oncol Pract*. 2023 Nov 20:OP2300494. doi: 10.1200/OP.23.00494. Online ahead of print. PMID: 37983586
 46. Bosi C, Bartha Á, Galbardi B, Notini G, Naldini MM, Licata L, Viale G, Mariani M, Pistilli B, Ali HR, André F, Piras M, Callari M, Barreca M, Locatelli A, Viganò L, **Criscitiello C**, Pustai L, Curigliano G, Györffy B, Dugo M, Bianchini G. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. *Eur J Cancer*. 2023 Dec;195:113379. doi: 10.1016/j.ejca.2023.113379. Epub 2023 Oct 11. PMID: 37913680
 47. Morganti S, Marra A, Gandini S, Ascione L, Ivanova M, Venetis K, Sajjadi E, Zagami P, Giugliano F, Taurelli Salimbeni B, Berton Giachetti PPM, Corti C, De Camilli E, Curigliano G, Fusco N, **Criscitiello C**. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study. *Eur J Cancer*. 2023 Oct 23;195:113397. doi: 10.1016/j.ejca.2023.113397. PMID: 37890353
 48. Venetis K, Pepe F, Pescia C, Cursano G, **Criscitiello C**, Frascarelli C, Mane E, Russo G, Taurelli Salimbeni B, Troncone G, Guerini Rocco E, Curigliano G, Fusco N, Malapelle U. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing. *Cancer Treat Rev*. 2023 Oct 13;121:102642. doi: 10.1016/j.ctrv.2023.102642. PMID: 37864956
 49. Antonarelli G, Salimbeni BT, Marra A, Esposito A, Locatelli MA, Trapani D, Pescia C, Fusco N, Curigliano G, **Criscitiello C**. The CDK4/6 Inhibitors Biomarker Landscape: the most Relevant Biomarkers of Response or Resistance for Further Research and Potential Clinical Utility. *Crit Rev Oncol Hematol*. 2023 Sep 30:104148. doi: 10.1016/j.critrevonc.2023.104148. PMID: 37783318
 50. Mazzarella L, Giugliano F, Nicolo E, Esposito A, Crimini E, Tini G, Uliano J, Corti C, D'Amico P, Trillo Aliaga P, Valenza C, Repetto M, Antonarelli G, Ascione L, Vivinet G, Berton Giachetti P, Minchella I, Belli C, Locatelli M, **Criscitiello C**, Curigliano G. Immune-Related Adverse Event Likelihood Score Identifies "Pure" IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population. *Oncologist*. 2023 Sep 16:oyad239. doi: 10.1093/oncolo/oyad239. PMID: 37715957
 51. Boscolo Bielo L, Trapani D, Repetto M, Crimini E, Valenza C, Belli C, **Criscitiello C**, Marra A, Subbiah V, Curigliano G. Variant of allele frequency: a decision-making tool in precision oncology? *Trends Cancer*. 2023 Sep 11:S2405-8033(23)00171-1. doi: 10.1016/j.trecan.2023.08.011. PMID: 37704501
 52. Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, **Criscitiello C**, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G,

- Giannarelli D, Scambia G. Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer. *NPJ Breast Cancer*. 2023 Sep 8;9(1):73. doi: 10.1038/s41523-023-00579-2.PMID: 37684252
53. Crimini E, Tini G, Tarantino P, Ascione L, Repetto M, Beria P, Ranghiero A, Marra A, Belli C, **Criscitiello C**, Esposito A, Guerini Rocco E, Barberis MCP, Mazzarella L, Curigliano G. Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience. *Oncologist*. 2023 Sep 5:oyad229. doi: 10.1093/oncolo/oyad229. Online ahead of print.PMID: 37669224
 54. Ascione L, Crimini E, Trapani D, Marra A, **Criscitiello C**, Curigliano G. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability. *Oncologist*. 2023 Sep 4:oyad246. Doi 10.1093/oncolo/oyad246. Online ahead of print.PMID: 37665782
 55. **Criscitiello C**, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, Castellan L, Arpino G, Conte P, Di Meco F, Gennari A, Guarneri V, Visani L, Livi L, Marchetti P, Puglisi F, Viale G, Del Mastro L, De Placido S, Curigliano G. Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread. *Cancer Treat Rev*. 2023 Aug 22;120:102618. doi: 10.1016/j.ctrv.2023.102618. Online ahead of print.PMID: 37639757
 56. Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey. *Crit Rev Oncol Hematol*. 2023 Aug 16;190:104103. doi: 10.1016/j.critrevonc.2023.104103. PMID: 37595344
 57. Nicolò E, Tarantino P, D'Ecclesiis O, Antonarelli G, Boscolo Bielo L, Marra A, Gandini S, Crimini E, Giugliano F, Zagami P, Corti C, Trapani D, Morganti S, Criscitiello C, Locatelli M, Belli C, Esposito A, Minchella I, Cristofanilli M, Tolaney SM, Curigliano G. Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents. *Oncologist*. 2023 Aug 7:oyad212. doi: 10.1093/oncolo/oyad212. Online ahead of print.PMID: 37548439
 58. Castellano G, Corti C, Boldrini L, Gervaso L, **Criscitiello C**, Curigliano G. Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials. *Cancer Treat Rev*. 2023 Sep;119:102601. doi: 10.1016/j.ctrv.2023.102601. Epub 2023 Jul 17. PMID: 37473517
 59. Ivanova M, Porta FM, Giugliano F, Frascarelli C, Sajjadi E, Venetis K, Cursano G, Mazzarol G, Guerini-Rocco E, Curigliano G, **Criscitiello C**, Fusco N. Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management. *Genes (Basel)*. 2023 May 26;14(6):1160. doi: 10.3390/genes14061160.PMID: 37372340
 60. Licata L, Viale G, Giuliano M, Curigliano G, Chavez-MacGregor M, Foldi J, Oke O, Collins J, Del Mastro L, Puglisi F, Montemurro F, Vernieri C, Gerratana L, Giordano S, Rognone A, Sica L, Gentilini OD, Cascinu S, Pusztai L, Giordano A, Criscitiello C, Bianchini G. Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer. *NPJ Breast Cancer*. 2023 Jun 8;9(1):51. doi: 10.1038/s41523-023-00559-6.PMID: 37291235

61. Corti C, De Angelis C, Bianchini G, Malorni L, Giuliano M, Hamilton E, Jeselsohn R, Jhaveri K, Curigliano G, **Criscitiello C**. Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? *Cancer Treat Rev.* 2023 Apr 28;117:102569. doi: 10.1016/j.ctrv.2023.102569. PMID: 37146385
62. Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, Corti C, Benvenuti C, Fucà G, Lobefaro R, Ligorio F, Provenzano L, Vingiani A, Del Vecchio M, Griguolo G, Sirico M, Bernocchi O, Marra A, Zagami P, Agostinetti E, Jacobs F, Di Mauro P, Esposito A, Giorgi CA, Lalli L, Boldrini L, Giacchetti PPB, Schianca AC, Guarneri V, Pedersini R, Losurdo A, Zambelli A, Generali D, *Criscitiello C*, Curigliano G, Pruneri G, de Braud F, Dieci MV, Vernieri C. Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. *NPJ Breast Cancer.* 2023 Apr 17;9(1):27. doi: 10.1038/s41523-023-00534-1. PMID: 37069173
63. Corso G, **Criscitiello C**, Nicosia L, Pesapane F, Vicini E, Magnoni F, Sibilio A, Zanzottera C, De Scalzi AM, Mannucci S, Marabelli M, Calvello M, Feroce I, Zagami P, Porta FM, Toesca A, Tarantino P, Nicolò E, Mazzarol G, La Vecchia C, Bonanni B, Leonardi MC, Veronesi P, Fusco N. Metaplastic breast cancer: an all-round multidisciplinary consensus. *Eur J Cancer Prev.* 2023 Apr 18. doi: 10.1097/CEJ.0000000000000794. PMID: 37021548
64. Corti C, Boscolo Bielo L, Schianca AC, Salimbeni BT, **Criscitiello C**, Curigliano G. Future potential targets of antibody-drug conjugates in breast cancer. *Breast.* 2023 Mar 24;69:312-322. doi: 10.1016/j.breast.2023.03.007. PMID: 3699662
65. Trillo P, Sandoval J, Trapani D, Nicolò E, Zagami P, Giugliano F, Tarantino P, Vivianet G, Ascione L, Friedlaender A, Esposito A, **Criscitiello C**, Curigliano G. Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases. *Eur J Cancer.* 2023 Mar 8;185:119-130. doi: 10.1016/j.ejca.2023.02.028. PMID: 36989828

66. Antonarelli G, Pieri V, Porta FM, Fusco N, Finocchiaro G, Curigliano G, **Criscitiello C**. Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation. *Cells*. 2023 Mar 8;12(6):840. doi: 10.3390/cells12060840. PMID: 36980181
67. Corti C, Giugliano F, Nicolò E, Tarantino P, **Criscitiello C**, Curigliano G. HER2-Low Breast Cancer: a New Subtype? *Curr Treat Options Oncol*. 2023 Mar 27. doi: 10.1007/s11864-023-01068-1. Online ahead of print. PMID: 36971965
68. Giugliano F, Carnevale Schianca A, Corti C, Ivanova M, Bianco N, Dellapasqua S, **Criscitiello C**, Fusco N, Curigliano G, Munzone E. Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. *Cancers (Basel)*. 2023 Feb 22;15(5):1385. doi: 10.3390/cancers15051385. PMID: 36900178
69. Repetto M, Crimini E, Boscolo Bielo L, Guerini-Rocco E, Ascione L, Bonfanti A, Zanzottera C, Mazzeo L, Ranghiero A, Belli C, **Criscitiello C**, Esposito A, Barberis MCP, Curigliano G. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience. *Eur J Cancer*. 2023 Jan 31;183:79-89. doi: 10.1016/j.ejca.2023.01.019. Online ahead of print. PMID: 36801623
70. Fusco N, Malapelle U, **Criscitiello C**. Editorial: Diagnosis and Treatment of Breast Cancer in 2022: The Rise of Novel Molecular Biomarkers. *Front Mol Biosci*. 2023 Jan 4;9:1117323. doi: 10.3389/fmolb.2022.1117323. eCollection 2022. PMID: 36660432
71. Morganti S, Ivanova M, Ferraro E, Ascione L, Vivinet G, Bonizzi G, Curigliano G, Fusco N, **Criscitiello C**. Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls. *Cancer Drug Resist*. 2022 Oct 20;5(4):971-980. doi: 10.20517/cdr.2022.55. eCollection 2022. PMID: 36627895
72. Ascione L, Zagami P, Nicolò E, Crimini E, Curigliano G, **Criscitiello C**. PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative. *J Pers Med*. 2022 Oct 31;12(11):1793. doi: 10.3390/jpm12111793. PMID: 36579519

73. Corti C, Cobanaj M, Dee EC, **Criscitiello C**, Tolaney SM, Celi LA, Curigliano G. Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care. *Cancer Treat Rev.* 2023 Jan;112:102498. doi: 10.1016/j.ctrv.2022.102498. Epub 2022 Dec 11. PMID: 36527795
74. Miglietta F, Cinquini M, Dieci MV, Cortesi L, **Criscitiello C**, Montemurro F, Del Mastro L, Zambelli A, Biganzoli L, Levaggi A, Delle Piane C, Marchiò C, Calabrese M, Fortunato L, Franco P, Meduri B, Fittipaldo VA, Gori S. PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology. *Breast.* 2022 Oct 29;66:293-304. doi: 10.1016/j.breast.2022.10.014. Online ahead of print. PMID: 36379199
75. **Criscitiello C**, Corti C. Breast Cancer Genetics: Diagnostics and Treatment. *Genes (Basel).* 2022 Sep 6;13(9):1593. doi: 10.3390/genes13091593. PMID: 36140761
76. Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, Cortés J, Harbeck N, Carey LA, **Criscitiello C**, Curigliano G. Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? *Eur J Cancer.* 2022 Jun 10;171:25-42. doi: 10.1016/j.ejca.2022.04.039. Online ahead of print. PMID: 35696887
77. Agostinetto E, Montemurro F, Puglisi F, **Criscitiello C**, Bianchini G, Del Mastro L, Intronà M, Tondini C, Santoro A, Zambelli A. Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. *Cancers (Basel).* 2022 Apr 25;14(9):2136. doi: 10.3390/cancers14092136. PMID: 35565264
78. Pérez-Fidalgo JA, **Criscitiello C**, Carrasco E, Regan MM, Leo AD, Ribí K, Adam V, Bedard PL. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer. *Future Oncol.* 2022 Apr 25. doi: 10.2217/fon-2022-0045. Online ahead of print. PMID: 35465733
79. Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-Rocco E, Viale G, Curigliano G, **Criscitiello C**, Fusco N. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the

- Spectrum of HER2 Positivity in Breast Cancer. *Front Mol Biosci.* 2022 Mar 15;9:834651. doi: 10.3389/fmolb.2022.834651. eCollection 2022. PMID: 35372498
80. Morganti S, Bianchini G, Giordano A, Giuliano M, Curigliano G, **Criscitiello C**. How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? *ESMO Open.* 2022 Mar 7;7(2):100428. doi: 10.1016/j.esmoop.2022.100428. Online ahead of print. PMID: 35272131
81. de Sire A, Lippi L, Venetis K, Morganti S, Sajjadi E, Curci C, Ammendolia A, **Criscitiello C**, Fusco N, Invernizzi M. Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials. *Front Oncol.* 2022 Jan 21;11:829875. doi: 10.3389/fonc.2021.829875. eCollection 2021. PMID: 35127539
82. Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivinet G, Bellerba F, Trapani D, Marra A, Esposito A, **Criscitiello C**, Viale G, Curigliano G. Evolution of low HER2 expression between early and advanced-stage breast cancer. *Eur J Cancer.* 2022 Mar;163:35-43. doi: 10.1016/j.ejca.2021.12.022. Epub 2022 Jan 13. PMID: 35032815
83. Corti C, Antonarelli G, **Criscitiello C**, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. *Cancer Treat Rev.* 2021 Dec 16;103:102324. doi: 10.1016/j.ctrv.2021.102324. Online ahead of print. PMID: 34953200
84. Trillo Aliaga P, Trapani D, Sandoval JL, Crimini E, Antonarelli G, Vivinet G, Morganti S, Corti C, Tarantino P, Friedlaender A, Belli C, Minchella I, Locatelli M, Esposito A, **Criscitiello C**, Curigliano G. Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. *Cancers (Basel).* 2021 Nov 20;13(22):5829. doi: 10.3390/cancers13225829. PMID: 34830983
85. Fusco N, Ragazzi M, Sajjadi E, Venetis K, Piciotti R, Morganti S, Santandrea G, Fanelli GN, Despini L, Invernizzi M, Cerbelli B, Scatena C, **Criscitiello C**. Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists.

- Histol Histopathol. 2021 Sep 29:18376. doi: 10.14670/HH-18-376. Online ahead of print. PMID: 34585734
86. **Criscitiello C**, Marra A, Morganti S, Zagami P, Gandini S, Esposito A, Curigliano G. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. *Eur J Cancer*. 2021 Nov;157:40-49. doi: 10.1016/j.ejca.2021.07.037. Epub 2021 Aug 31. PMID: 34474219
87. **Criscitiello C**, Spurden D, Piercy J, Rider A, Williams R, Mitra D, Wild R, Corsaro M, Kurosky SK, Law EH. Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer. *Clin Ther*. 2021 Jul;43(7):1228-1244.e4. doi: 10.1016/j.clinthera.2021.04.020. Epub 2021 Jul 11. PMID: 34256965
88. **Criscitiello C**, Guerini-Rocco E, Viale G, Fumagalli C, Sajjadi E, Venetis K, Piciotti R, Invernizzi M, Malapelle U, Fusco N. Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. *Anticancer Agents Med Chem*. 2021 Jul 6. doi: 10.2174/1871520621666210706144112. Online ahead of print. PMID: 34229592
89. Venetis K, Piciotti R, Sajjadi E, Invernizzi M, Morganti S, **Criscitiello C**, Fusco N. Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management. *Cells*. 2021 Jun 2;10(6):1377. doi: 10.3390/cells10061377. PMID: 34199522
90. Meattini I, Becherini C, Bernini M, Bonzano E, **Criscitiello C**, De Rose F, De Santis MC, Fontana A, Franco P, Gentilini OD, Livi L, Meduri B, Parisi S, Pasinetti N, Prisco A, Rocco N. Breast reconstruction and radiation therapy: An Italian expert Delphi consensus statements and critical review. *Cancer Treat Rev*. 2021 Sep;99:102236. doi: 10.1016/j.ctrv.2021.102236. Epub 2021 May 27. PMID: 34126314
91. Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, **Criscitiello C**, Awada A, Loi S. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in

- breast cancer therapeutics. *Expert Opin Biol Ther.* 2021 Jul;21(7):945-962. doi: 10.1080/14712598.2021.1936494. Epub 2021 Jun 15. PMID: 34043927
92. Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, **Criscitiello C**, Tarantino P, Curigliano G. Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. *Cancer Treat Rev.* 2021 Apr 9;97:102205. doi: 10.1016/j.ctrv.2021.102205. Online ahead of print. PMID: 33878560
93. Fusco N, Malapelle U, Fassan M, Marchiò C, Buglioni S, Zupo S, **Criscitiello C**, Vigneri P, Dei Tos AP, Maiorano E, Viale G. PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. *Front Oncol.* 2021 Mar 25;11:644737. doi: 10.3389/fonc.2021.644737. eCollection 2021.PMID: 33842357
94. Morgan G, Tagliamento M, Lambertini M, Devnani B, Westphalen B, Dienstmann R, Bozovic-Spasojevic I, Calles A, **Criscitiello C**, Curioni A, Garcia AM, Lamarca A, Pilotto S, Scheffler M, Strijbos M, Wong R, de Azambuja E, Peters S. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. *ESMO Open.* 2021 Apr 7;6(2):100104. doi: 10.1016/j.esmoop.2021.100104. Online ahead of print.PMID: 33838532
95. Rocco N, Catanuto G, Cinquini M, Audretsch W, Benson J, **Criscitiello C**, Di Micco R, Kovacs T, Kuerer H, Lozza L, Montagna G, Moschetti I, Nafissi N, O'Connell RL, Oliveri S, Pau L, Scaperrotta G, Thoma A, Winters Z, Nava MB. Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations. *Breast.* 2021 Feb 26;57:25-35. doi: 10.1016/j.breast.2021.02.013. Online ahead of print. PMID: 33711697
96. Corti C, **Criscitiello C**. Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. *ESMO Open.* 2021 Mar 3;6(2):100063. doi: 10.1016/j.esmoop.2021.100063. Online ahead of print. PMID: 33676293

97. Rocco N, Montagna G, **Criscitello C**, Nava MB, Privitera F, Taher W, Gloria A, Catanuto G. Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients. *Genes (Basel)*. 2021 Feb 10;12(2):253. doi: 10.3390/genes12020253. PMID: 33578759
98. Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *NPJ Breast Cancer*. 2020 May 12;6(1):15. doi: 10.1038/s41523-020-0155-1. PMID: 33574324
99. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *NPJ Breast Cancer*. 2020 May 12;6(1):17. doi: 10.1038/s41523-020-0156-0. PMID: 33574291

100. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer*. 2020 May 12;6(1):16. doi: 10.1038/s41523-020-0154-2. PMID: 33574288
101. **Criscitiello C**, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. *J Hematol Oncol*. 2021 Jan 28;14(1):20. doi: 10.1186/s13045-021-01035-z. PMID: 33509252
102. Esposito A, Marra A, Bagnardi V, Frassoni S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F, Venetis K, Mazzarella L, Viale G, Fusco N, **Criscitiello C**, Curigliano G. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. *Eur J Cancer*. 2021 Jan 22;145:197-209. doi: 10.1016/j.ejca.2020.12.028. PMID: 33493979
103. Tarantino P, Gandini S, Trapani D, **Criscitiello C**, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2021 Jan 19:103223. doi: 10.1016/j.critrevonc.2021.103223. PMID: 33482345.

104. Invernizzi M, de Sire A, Lippi L, Venetis K, Sajjadi E, Gimigliano F, Gennari A, **Criscitiello C**, Cisari C, Fusco N. Impact of Rehabilitation on Breast Cancer Related Fatigue: A Pilot Study. *Front Oncol.* 2020 Oct 21;10:556718. doi: 10.3389/fonc.2020.556718. eCollection 2020.
105. Marra A, Trapani D, Viale G, **Criscitiello C**, Curigliano G. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. *NPJ Breast Cancer.* 2020 Oct 16;6:54. doi: 10.1038/s41523-020-00197-2. eCollection 2020. PMID: 33088912
106. Rocco N, Montagna G, di Micco R, Benson J, **Criscitiello C**, Chen L, Di Pace B, Colmenarejo AJE, Harder Y, Karakatsanis A, Maglia A, Mele M, Nafissi N, Ferreira PS, Taher W, Tejerina A, Vinci A, Nava M, Catanuto G. The impact of the COVID-19 pandemic on surgical management of breast cancer: global trends and future perspectives. *Oncologist.* 2020 Oct 12. doi: 10.1002/onco.13560.
107. Tarantino P, Marra A, Gandini S, Minotti M, Pricolo P, Signorelli G, **Criscitiello C**, Locatelli M, Belli C, Bellomi M, Curigliano G. Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents. *Eur J Cancer.* 2020 Sep 23;139:92-98. doi: 10.1016/j.ejca.2020.08.026
108. Corti C, Crimini E, **Criscitiello C**, Trapani D, Curigliano G. Adjuvant treatment of early male breast cancer. *Curr Opin Oncol.* 2020 Aug 26. doi: 10.1097/CCO.0000000000000678. Online ahead of print. PMID: 32852309
109. **Criscitiello C**, Marra A, Morganti S, Zagami P, Viale G, Esposito A, Curigliano G. Pre-treatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials. *Oncologist.* 2020 Aug 12. doi: 10.1634/theoncologist.2020-0518. Online ahead of print. PMID: 32785940
110. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY,

- Pentheroudakis G; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol*. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31. PMID: 32745693
111. **Criscitiello C**, Vingiani A, Maisonneuve P, Viale G, Viale G, Curigliano G. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer. *Breast Cancer Res Treat*. 2020 Sep;183(2):347-354. doi: 10.1007/s10549-020-05771-7. Epub 2020 Jul 3. PMID: 32621251
112. Fusco N, Sajjadi E, Venetis K, Gaudioso G, Lopez G, Corti C, Rocco EG, **Criscitiello C**, Malapelle U, Invernizzi M. PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? *Genes (Basel)*. 2020 Jun 28;11(7):719. doi: 10.3390/genes11070719. PMID: 32605290
113. Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, **Criscitiello C**, Esposito A, Curigliano G. Pharmacological management of male breast cancer. *Expert Opin Pharmacother*. 2020 Jun 4;1-12. doi: 10.1080/14656566.2020.1763305.
114. de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, **Criscitiello C**, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. *ESMO Open*. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793.
115. Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *NPJ Breast Cancer*. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1. eCollection 2020.

116. Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klausen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *NPJ Breast Cancer*. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. eCollection 2020.
117. Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International

- Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2020 May 12;6:16. doi: 10.1038/s41523-020-0154-2. eCollection 2020.
118. Diana A, Carlino F, Franzese E, Oikonomidou O, **Criscitiello C**, De Vita F, Ciardiello F, Orditura M. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. *Cancers (Basel)*. 2020 Mar 29;12(4):819. doi: 10.3390/cancers12040819.
119. Lambertini M, Toss A, Passaro A, **Criscitiello C**, Cremolini C, Cardone C, Loupakis F, Viscardi G, Meattini I, Dieci MV, Ferrara R, Giusti R, Maio MD. ESMO Open. 2020 Mar;5(2). pii: e000759. doi: 10.1136/esmooopen-2020-000759. PMID: 32229501
120. **Criscitiello C**, Curigliano G. Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours. *Eur J Cancer*. 2020
121. Curigliano G, Bagnardi V, Ghioni M, Louahed J, Brichard V, Lehmann FF, Marra A, Trapani D, **Criscitiello C**, Viale G. Expression of tumor-associated antigens in breast cancer subtypes. *Breast*. 2019
122. Punzi S, Balestrieri C, D'Alesio C, Bossi D, Dellino GI, Gatti E, Pruneri G, **Criscitiello C**, Lovati G, Meliksetyan M, Carugo A, Curigliano G, Natoli G, Pelicci PG, Lanfranccone L. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. *Breast Cancer Res*. 2019
123. **Criscitiello C**, Viale G, Curigliano G. Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. *Curr Opin Oncol*. 2019
124. Park JH, Jonas SF, Bataillon G, **Criscitiello C**, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, André F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol*. 2019

125. Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, **Criscitiello C**, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). *Cancers (Basel)*. 2019 Aug 8;11(8).
126. Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, **Criscitiello C**, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. *Eur J Cancer*. 2019
127. **Criscitiello C**, Curigliano G. Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? *Eur J Cancer*. 2019
128. Punzi S, Meliksetian M, Riva L, Marocchi F, Pruneri G, **Criscitiello C**, Orsi F, Spaggiari L, Casiraghi M, Della Vigna P, Luzi L, Curigliano G, Pelicci PG, Lanfrancone L. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. *Cells*. 2019
129. **Criscitiello C**, Viale G, Curigliano G. Peptide vaccines in early breast cancer. *Breast*. 2019
130. Esposito A, Viale G, **Criscitiello C**, Curigliano G. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. *Expert Rev Clin Pharmacol*. 2018
131. Preusser M, De Mattos-Arruda L, Thill M, **Criscitiello C**, Bartsch R, Ruhstaller T, de Azambuja E, Zielinski CC. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion. *ESMO Open*. 2018 Aug 20
132. Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, **Criscitiello C**, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi

- E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TRENd trial. *Ann Oncol*. 2018 Jun 11.
133. **Criscitiello C**, Santangelo M, Loupakis F. Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers. *Biomed Res Int*. 2018 Mar 20
134. **Criscitiello C**, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, Curigliano G. Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. *Eur J Cancer*. 2018 Jul
135. Prager GW, Braga S, Bystricky B, Qvortrup C, **Criscitiello C**, Esin E, Sonke GS, Martínez GA, Frenel JS, Karamouzis M, Strijbos M, Yazici O, Bossi P, Banerjee S, Troiani T, Eniu A, Ciardiello F, Tabernero J, Zielinski CC, Casali PG, Cardoso F, Douillard JY, Jezdic S, McGregor K, Bricalli G, Vyas M, Ilbawi A. Global cancer control: responding to the growing burden, rising costs and inequalities in access. *ESMO Open*. 2018 Feb 2
136. Arruda LM, **Criscitiello C**, Lambertini M, Argiles G. ESMO Leaders Generation Programme: an alumni insight. *ESMO Open*. 2018 Jan 29
137. **Criscitiello C**, Viale G, Curigliano G, Goldhirsch A. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. *Breast Cancer (Dove Med Press)*. 2018 Jan 30
138. Duso BA, Trapani D, Viale G, **Criscitiello C**, D'Amico P, Belli C, Mazzearella L, Locatelli M, Minchella I, Curigliano G. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother*. 2018 Feb;19
139. Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, **Criscitiello C**, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja. The use of

- breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. *E. Eur J Cancer*. 2017 Dec 8.
140. **Criscitiello C**, Bagnardi V, Pruneri G, Vingiani A, Esposito A, Rotmensz N, Curigliano G. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. *Eur J Cancer*. 2017 Nov 15
141. Perri F, Buono G, Schettini F, Arpino G, Bianco R, **Criscitiello C**, De Placido S, Giuliano M. The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? *Anticancer Agents Med Chem*. 2017 Nov 2
142. **Criscitiello C**, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer. *Ann Oncol*. 2017 Oct 25
143. **Criscitiello C**, Viale G, Curigliano G. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. *Curr Opin Oncol*. 2017 Nov;29
144. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, **Criscitiello C**, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison

KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Adv Anat Pathol. 2017 Aug 2

145. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, **Criscitiello C**, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast

- Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Adv Anat Pathol*. 2017 Sep;24
146. Solinas C, Carbognin L, De Silva P, **Criscitiello C**, Lambertini M. Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. *Breast*. 2017 Jul 20
147. Trapani D, Esposito A, **Criscitiello C**, Mazzearella L, Locatelli M, Minchella I, Minucci S, Curigliano G. Entinostat for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2017 Aug;26
148. Curigliano G, **Criscitiello C**. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. *J Clin Oncol*. 2017 Aug 10.
149. Curigliano G, **Criscitiello C**, Esposito A, Intra M, Minucci S. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. *Expert Opin Drug Metab Toxicol*. 2017 Apr 11.
150. Esposito A, **Criscitiello C**, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. *Curr Oncol Rep*. 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y. Review.
151. Curigliano G, **Criscitiello C**, Esposito A, Pruneri G. Over-using chemotherapy in the adjuvant setting. *Breast*. 2017 Feb;31:303-308. doi: 10.1016/j.breast.2016.11.011.
152. Santangelo ML, Grifasi C, **Criscitiello C**, Giuliano M, Calogero A, Dodaro C, Incollingo P, Rupealta N, Candida M, Chiacchio G, Riccio E, Pisani A, Tammaro V, Carlomagno N. Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. *Aging Clin Exp Res*. 2016 Nov 11. [Epub ahead of print] Review. PMID: 27837464
153. **Criscitiello C**, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy

- for breast cancer in the modern era: Are we losing the opportunity? *Eur J Surg Oncol*. 2016 Oct 29. pii: S0748-7983(16)30949-0. doi: 10.1016/j.ejso.2016.10.011. [Epub ahead of print] Review. PMID: 27825710
154. D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, **Criscitiello C**, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfranccone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth. *Oncotarget*. 2016 Oct 13. doi: 10.18632/oncotarget.12646. [Epub ahead of print] PMID: 27779108
155. **Criscitiello C**, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev*. 2016 Oct 6;50:205-207. doi: 10.1016/j.ctrv.2016.09.019. [Epub ahead of print] Review. PMID: 27744144
156. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O'Brien C, Walter K, Huw LY, **Criscitiello C**, Laios I, Jose V, Brown DN, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart MJ, Michiels S, Lackner MR, Sotiriou C, Loi S. *Ann Oncol*. 2016 Oct;27(10):1860-6. doi: 10.1093/annonc/mdw286. PMID: 27672107
157. Migali C, Milano M, Trapani D, **Criscitiello C**, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Ther Adv Med Oncol*. 2016 Sep;8(5):360-74. doi: 10.1177/1758834016658423. Review. PMID: 27583028
158. Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M; MINDACT Investigators. 70-

- Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. *N Engl J Med.* 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253. PMID: 27557300
159. Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, **Criscitiello C**, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Canello G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat.* 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2. PubMed PMID: 27372069.
160. **Criscitiello C**, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, Goldhirsch A, Curigliano G. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. *Anticancer Res.* 2016 Jul;36(7):3537-40. PubMed PMID: 27354620.
161. **Criscitiello C**, Bagnardi V, Esposito A, Gelao L, Santillo B, Viale G, Rotmensz N, Goldhirsch A, Curigliano G. Impact of autoimmune diseases on outcome of patients with early breast cancer. *Oncotarget.* 2016 Jun 13. doi: 10.18632/oncotarget.9966. [Epub ahead of print] PubMed PMID: 27323400.
162. Curigliano G, Cardinale D, Dent S, **Criscitiello C**, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA Cancer J Clin.* 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. Review. PubMed PMID: 26919165.
163. Santangelo M, Esposito A, Tammaro V, Calogero A, **Criscitiello C**, Roberti G, Candida M, Rupealta N, Pisani A, Carlomagno N. What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review. *Int J Surg.* 2016 Apr;28 Suppl 1:S172-6. doi: 10.1016/j.ijsu.2015.12.046. Epub 2015 Dec 18. Review. PubMed PMID: 26708862.

164. Esposito A, **Criscitiello C**, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. *Pharmacol Ther.* 2016 Jan;157:120-4. doi: 10.1016/j.pharmthera.2015.11.007. Epub 2015 Nov 23. Review. PubMed PMID: 26615782.
165. Esposito A, **Criscitiello C**, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. *Curr Opin Oncol.* 2015 Nov;27(6):445-51. doi: 10.1097/CCO.0000000000000225. Review. PubMed PMID: 26447875.
166. **Criscitiello C**, Esposito A, De Placido S, Curigliano G. Targeting fibroblast growth factor receptor pathway in breast cancer. *Curr Opin Oncol.* 2015 Nov;27(6):452-6. doi: 10.1097/CCO.0000000000000224. Review. PubMed PMID: 26397764.
167. Esposito A, **Criscitiello C**, Gelao L, Pravettoni G, Locatelli M, Minchella I, Di Leo M, Liuzzi R, Milani A, Massaro M, Curigliano G. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. *Cancer Treat Rev.* 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11. Review. PubMed PMID: 26386985.
168. **Criscitiello C**, Curigliano G. Immunotherapy of Breast Cancer. *Prog Tumor Res.* 2015;42:30-43. doi: 10.1159/000437183. Epub 2015 Sep 4. Review. PubMed PMID: 26377084.
169. **Criscitiello C**, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? *Eur J Surg Oncol.* 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. Review. PubMed PMID: 26238477.
170. Santangelo ML, **Criscitiello C**, Renda A, Federico S, Curigliano G, Dodaro C, Scotti A, Tammaro V, Calogero A, Riccio E, Pisani A, Carlomagno N. Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study.

- Biomed Res Int. 2015;2015:183523. doi: 10.1155/2015/183523. Epub 2015 Jun 22. PubMed PMID: 26185750; PubMed Central PMCID: PMC4491567.
171. Dieci MV, **Criscitiello C**, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delalogue S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol.* 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. PubMed PMID: 26109735.
172. Esposito A, **Criscitiello C**, Curigliano G. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. *J Natl Cancer Inst Monogr.* 2015 May;2015(51):51-5. doi: 10.1093/jncimonographs/lgv012. PubMed PMID: 26063887.
173. Esposito A, **Criscitiello C**, Curigliano G. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. *Ecancermedicalsecience.* 2015 Mar 31;9:518. doi: 10.3332/ecancer.2015.518. eCollection 2015. PubMed PMID: 25932042; PubMed Central PMCID: PMC4404037.
174. Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, **Criscitiello C**, Viale G, Goldhirsch A. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. *Breast.* 2015 Jun;24(3):263-71. doi: 10.1016/j.breast.2015.02.036. Epub 2015 Mar 12. PubMed PMID: 25772326.
175. Carlomagno N, Schonauer F, Tammaro V, Di Martino A, **Criscitiello C**, Santangelo ML. A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report. *J Med Case Rep.* 2015 Jan 26;9:13. doi: 10.1186/1752-1947-9-13. PubMed PMID: 25619316; PubMed Central PMCID: PMC4407615.

176. **Criscitiello C**, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. *Cancer Treat Rev.* 2015 Feb;41(2):61-8. doi: 10.1016/j.ctrv.2014.12.001. Epub 2014 Dec 8. Review. PubMed PMID: 25499997.
177. **Criscitiello C**, Esposito A, Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. *Curr Opin Oncol.* 2014 Nov;26(6):551-5. doi: 10.1097/CCO.000000000000122. Review. PubMed PMID: 25279962.
178. Lammers P, **Criscitiello C**, Curigliano G, Jacobs I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. *Pharmaceuticals (Basel).* 2014 Sep 17;7(9):943-53. doi: 10.3390/ph7090943. PubMed PMID: 25232798; PubMed Central PMCID: PMC4190498.
179. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehner FL, Penault-Llorca F, Perez EA, Thompson EA, SymmansWF, Richardson AL, Brock J, **Criscitiello C**, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S; International TILs Working Group 2014. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol.* 2015 Feb;26(2):259-71. doi: 10.1093/annonc/mdu450. Epub 2014 Sep 11. PubMed PMID: 25214542.
180. **Criscitiello C**, Viale G, Esposito A, Curigliano G. Dinaciclib for the treatment of breast cancer. *Expert Opin Investig Drugs.* 2014 Sep;23(9):1305-12. doi: 10.1517/13543784.2014.948152. Epub 2014 Aug 8. Review. PubMed PMID: 25107301.
181. Esposito A, **Criscitiello C**, Salè EO, Curigliano G. Optimal adjuvant chemotherapy in breast cancer: selection of agents. *Expert Rev Clin Pharmacol.* 2014 Sep;7(5):605-11. doi: 10.1586/17512433.2014.945429. Epub 2014 Aug 1. Review. PubMed PMID: 25080998.

182. **Criscitiello C**, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. *Breast Cancer Res.* 2014;16(2):205. Review. PubMed PMID: 25032257; PubMed Central PMCID: PMC4052940.
183. Locatelli M, **Criscitiello C**, Esposito A, Minchella I, Goldhirsch A, Cipolla C, Curigliano G. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. *Target Oncol.* 2015 Mar;10(1):27-43. doi: 10.1007/s11523-014-0325-x. Epub 2014 Jun 27. Review. PubMed PMID: 24970120.
184. Ades F, Zardavas D, Pinto AC, **Criscitiello C**, Aftimos P, de Azambuja E. Cardiotoxicity of systemic agents used in breast cancer. *Breast.* 2014 Aug;23(4):317-28. doi: 10.1016/j.breast.2014.04.002. Epub 2014 May 1. Review. PubMed PMID: 24794210.
185. Gelao L, **Criscitiello C**, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G. Dendritic cell-based vaccines: clinical applications in breast cancer. *Immunotherapy.* 2014;6(3):349-60. doi: 10.2217/imt.13.169. Review. PubMed PMID: 24762078.
186. Curigliano G, **Criscitiello C**. Successes and limitations of targeted cancer therapy in breast cancer. *Prog Tumor Res.* 2014;41:15-35. doi: 10.1159/000355896. Epub 2014 Feb 17. Review. PubMed PMID: 24727984.
187. **Criscitiello C**, Azim HA, de Azambuja E, Rubio IT. Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. *Ann Oncol.* 2014 Apr;25(4):910-1. doi: 10.1093/annonc/mdu034. PubMed PMID: 24667722.
188. **Criscitiello C**, Gelao L, Viale G, Esposito A, Curigliano G. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. *Expert Opin Investig*

- Drugs. 2014 May;23(5):599-610. doi: 10.1517/13543784.2014.895323. Epub 2014 Mar 5. Review. PubMed PMID: 24597540.
189. Gelao L, **Criscitiello C**, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". *Toxins (Basel)*. 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914. Review. PubMed PMID: 24594636; PubMed Central PMCID: PMC3968368.
190. Dieci MV, **Criscitiello C**, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2014 Mar;25(3):611-8. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: *Ann Oncol*. 2015 Jul;26(7):1518. PubMed PMID: 24401929; PubMed Central PMCID: PMC3933248.
191. **Criscitiello C**, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, Curigliano G. Immune approaches to the treatment of breast cancer, around the corner? *Breast Cancer Res*. 2014 Feb 25;16(1):204. doi: 10.1186/bcr3620. Review. PubMed PMID: 25774617; PubMed Central PMCID: PMC3978442.
192. **Criscitiello C**, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, Curigliano G. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. *Breast*. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4. PubMed PMID: 24314620.
193. Esposito A, Bardelli A, **Criscitiello C**, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, Curigliano G. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. *Cancer Treat Rev*.

- 2014 Jun;40(5):648-55. doi: 10.1016/j.ctrv.2013.10.003. Epub 2013 Oct 23. Review. PubMed PMID: 24184333.
194. **Criscitiello C**, Disalvatore D, Santangelo M, Rotmensz N, Bazolli B, Maisonneuve P, Goldhirsch A, Curigliano G. No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis. *Cancer Epidemiol Biomarkers Prev.* 2014 Jan;23(1):215-7. doi: 10.1158/1055-9965.EPI-13-1041. Epub 2013 Oct 28. PubMed PMID: 24165579.
195. **Criscitiello C**, Curigliano G. Immunotherapeutics for breast cancer. *Curr Opin Oncol.* 2013 Nov;25(6):602-8. doi: 10.1097/CCO.000000000000020. Review. PubMed PMID: 24076578.
196. Curigliano G, **Criscitiello C**, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. *Breast.* 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. Review. PubMed PMID: 24074802.
197. Curigliano G, **Criscitiello C**, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Best management of locally advanced inoperable breast cancer. *EJC Suppl.* 2013 Sep;11(2):289-90. doi: 10.1016/j.ejcsup.2013.07.052. Review. PubMed PMID: 26217148; PubMed Central PMCID: PMC4041552.
198. **Criscitiello C**. Tumor-associated antigens in breast cancer. *Breast Care (Basel).* 2012 Aug;7(4):262-6. doi: 10.1159/000342164. PubMed PMID: 23904827; PubMed Central PMCID: PMC3515784.
199. Curigliano G, **Criscitiello C**, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). *Clin Cancer Res.* 2013 Oct 15;19(20):5564-71. doi: 10.1158/1078-0432.CCR-12-3697. Epub 2013 Jul 29. Review. PubMed PMID: 23897901.
200. Gelao L, **Criscitiello C**, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, Curigliano G. Tumour dormancy and clinical implications in breast cancer.

- Ecancermedicalsecience. 2013 May 21;7:320. doi: 10.3332/ecancer.2013.320. Print 2013. PubMed PMID: 23717341; PubMed Central PMCID: PMC3660156.
201. Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, **Criscitiello C**, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, Curigliano G. Locoregional recurrence in patients with HER2 positive breast cancer. *Breast*. 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1. PubMed PMID: 23642529.
202. Curigliano G, **Criscitiello C**, Andrè F, Colleoni M, Di Leo A. Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? *Ecancermedicalsecience*. 2013 Mar 26;7:299. doi: 10.3332/ecancer.2013.299. Print 2013. PubMed PMID: 23589728; PubMed Central PMCID: PMC3622446.
203. **Criscitiello C**, Azim HA Jr, Agbor-tarh D, de Azambuja E, Piccart M, Baselga J, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT. Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial. *Ann Oncol*. 2013 Aug;24(8):1980-5. doi: 10.1093/annonc/mdt129. Epub 2013 Apr 7. PubMed PMID: 23567146.
204. **Criscitiello C**, Curigliano G. HER2 signaling pathway and trastuzumab cardiotoxicity. *Future Oncol*. 2013 Feb;9(2):179-81. doi: 10.2217/fon.12.193. PubMed PMID: 23414468.
205. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, **Criscitiello C**, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii155-66. PubMed PMID: 22997448.

206. **Criscitiello C**, Azim HA Jr, Schouten PC, Linn SC, Sotiriou C. Understanding the biology of triple-negative breast cancer. *Ann Oncol.* 2012 Aug;23 Suppl 6:vi13-8. Review. PubMed PMID: 23012296.
207. **Criscitiello C**, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, de Azambuja E, Piccart-Gebhart MJ. Targeted therapies in breast cancer: are heart and vessels also being targeted? *Breast Cancer Res.* 2012 Jun 19;14(3):209. Review. PubMed PMID: 22713170; PubMed Central PMCID: PMC3446327.
208. Brollo J, Curigliano G, Disalvatore D, Marrone BF, **Criscitiello C**, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. *Cancer Treat Rev.* 2013 Feb;39(1):44-50. doi: 10.1016/j.ctrv.2012.03.009. Epub 2012 Apr 27. Review. PubMed PMID: 22541668.
209. Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, **Criscitiello C**, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. *J Clin Oncol.* 2012 Jun 1;30(16):1996-2004. doi: 10.1200/JCO.2011.39.5624. Epub 2012 Apr 16. PubMed PMID: 22508827.
210. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, **Criscitiello C**, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. *Clin Cancer Res.* 2012 Mar 1;18(5):1341-51. doi: 10.1158/1078-0432.CCR-11-2599. Epub 2012 Jan 18. PubMed PMID: 22261811.
211. Curigliano G, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolé F, **Criscitiello C**, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. *Expert Opin Investig Drugs.* 2012 Feb;21(2):191-204. doi: 10.1517/13543784.2012.651456. Epub 2012 Jan 10. Review. PubMed PMID: 22229343.

212. **Criscitiello C**, Fumagalli D, Saini KS, Loi S. Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection. *Onco Targets Ther.* 2010 Dec 17;4:1-11. doi: 10.2147/OTT.S10155. PubMed PMID: 21552410; PubMed Central PMCID: PMC3084302.
213. Ignatiadis M, Rothé F, Chaboteaux C, Durbecq V, Rouas G, **Criscitiello C**, Metallo J, Kheddoumi N, Singhal SK, Michiels S, Veys I, Rossari J, Larsimont D, Carly B, Pestrin M, Bessi S, Buxant F, Liebens F, Piccart M, Sotiriou C. HER2-positive circulating tumor cells in breast cancer. *PLoS One.* 2011 Jan 10;6(1):e15624. doi: 10.1371/journal.pone.0015624. PubMed PMID: 21264346; PubMed Central PMCID: PMC3018524.
214. **Criscitiello C**, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer. *Curr Opin Oncol.* 2010 Nov;22(6):552-8. doi: 10.1097/CCO.0b013e32833de186. Review. PubMed PMID: 20706122.
215. De Laurentiis M, **Criscitiello C**, Montanino A, Falato C, Plaitano M. [Exemestane in the treatment of breast carcinoma: recent findings]. *Tumori.* 2008 Jan-Feb;94(1):suppl 10-21. Italian. PubMed PMID: 18468352.
216. De Laurentiis M, Canello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, **Criscitiello C**, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. *J Clin Oncol.* 2008 Jan 1;26(1):44-53. doi: 10.1200/JCO.2007.11.3787. PubMed PMID: 18165639.

La sottoscritta, Carmen Criscitiello, nata ad Avellino il 22/11/1980, consapevole delle sanzioni penali previste in caso di dichiarazioni mendaci e falsità negli atti, ai sensi dell'art. 76 del D.P.R. 445/2000, dichiara che i titoli indicati nel presente documento sono stati effettivamente conseguiti e sono conformi agli originali, ai sensi degli articoli 46 e 47 del D.P.R. 445/2000.

Ai sensi dell'art. 13 del Regolamento UE 679/2016 (“GDPR”) e del D.Lgs. 30 giugno 2003, n. 196, la sottoscritta autorizza il trattamento dei propri dati personali per le finalità connesse alla presente procedura selettiva.

Milano, 03/07/2025

Carmen Criscitiello